АНТИМИКРОБНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПОЛИМЕРНЫЕ СТАБИЛИЗАТОРЫ

Настоящее изобретение относится к медицине и описывает жидкую антимикробную композицию, содержащую (1) смесь йодидных анионов и тиоцианатных анионов, причем весовое соотношение йодидных анионов к тиоционатным анионам составляет от 0,2:1 до 20:1; (2) перйодную кислоту или ее соль; и (3) по меньшей мере, один полимер или сополимер, содержащий в качестве мономерных звеньев (а) 5-100 вес.%, по меньшей мере, одного моноэтиленненасыщенного мономера, содержащего азот- и/или фосфорсодержащие группы, (b) 0-95 вес.%, по меньшей мере, одного моноэтиленненасыщенного сомономера, содержащего кислотные группы, (с) 0-75 вес.%, по меньшей мере, одного дополнительного сомономера, выбранного из группы, включающей моноэтиленненасыщенные мономеры, отличные от (а) и (b), и мономеры, свободные от этиленненасыщенных групп, пригодные для образования полиэфиров, и (d) 0-5 вес.% сшивающих сомономеров, содержащих, по меньшей мере, две этиленненасыщенные группы. Техническим результатом изобретения является повышение ...

СРЕДСТВО АНТИМИКРОБНОГО ДЕЙСТВИЯ

Изобретение относится к химико-фармацевтической промышленности. Изобретение касается антимикробного средства в форме свечей, содержащего йод, предназначеного для лечения воспалительных заболеваний женской половой сферы. Средство антимикробного действия, выполненное в форме суппозитория, включающее активное вещество йод и наполнитель, отличающееся тем, что активное вещество выполнено в форме комплекса йод-ДМСО (диметилсульфоксид) в соотношении 1:(1-10), а в качестве наполнителя оно содержит жирорастворимую основу, при этом содержание йода в суппозитории 10 мг. Свечи проявляют широкий спектр антимикробного действия, при этом не оказывая побочного действия. Активное вещество проникает в глубину тканей, селективно воздействует на микроорганизмы. Заявленное средство удобно в применении, не пачкает одежду и кожу. 4 з.п. ф-лы, 2 табл.

Продукт для пероральной доставки

Изобретение относится к композиции для пероральной доставки витаминов и минеральных веществ субъекту, содержащей витамины, минеральные вещества, ароматизаторы или вкусовые агенты, связывающее вещество, которое включает сахарный спирт, представляющий собой изомальт, и экспициенты, выбранные из прежелатинизированного крахмала и карбоксиметилцеллюлозы, где композиция может растворяться во рту указанного субъекта или может быть пережевана и проглочена указанным субъектом и где калорийность композиции составляет приблизительно 5 калорий, а твердость композиции составляет от 17 кгс до 28 кгс. 7 з.п. ф-лы, 8 пр., 10 табл.

МИКРОЭЛЕМЕНТНЫЙ ПРЕПАРАТ ДЛЯ ЖИВОТНЫХ

Изобретение относится к животноводству, в частности к микроэлементному препарату для животных. Препарат содержит 2Na- или 2K-соль этилендиамин-N,N-диянтарной кислоты в количестве 20,0-50,0 мас.%; Na- или К-соль аминокислоты или аминокислоту в количестве 3,0-15,0 мас.%; железо(III) в количестве 0,3-3,0 мас.%; магний(II) в количестве 0,3-3,0 мас.%; марганец(II) в количестве 0,4-2,5 мас.%; медь(II) в количестве 0,05-0,25 мас.%; цинк(II) в количестве 0,3-2,5 мас.%; кобальт(II) в количестве 0,005-0,05 мас.%; селен(IV) в количестве 0,01-0,03 мас.%; йод(I) в количестве 0,03-0,08 мас.%; вода остальное. Изобретение обеспечивает высокую эффективность применения заявленного препарата для профилактики и лечения хронической интоксикации тяжелыми металлами. 1 з.п. ф-лы, 5 табл., 4 пр.

Состав для стимуляции метаболических процессов, системы иммунитета, профилактики заболеваний диареей

Группа изобретений относится к области ветеринарии и предназначена для стимуляции обменных процессов и системы иммунитета, профилактики желудочно-кишечных заболеваний и повышения ростовой активности молодняка сельскохозяйственных животных. Заявлен состав, обладающий метаболической, иммуномодулирующей и антимикробной активностью для профилактики желудочно-кишечных заболеваний с диарейным синдромом, включающий янтарную кислоту, йодинол и АСД второй фракции при следующем соотношении компонентов на 1000 мл водного раствора: янтарная кислота - 10,0 г, йодинол - 250 мл, АСД второй фракции - 40 мл. Также заявлен состав, обладающий метаболической, иммуномодулирующей и антимикробной активностью для профилактики желудочно-кишечных заболеваний с диарейным синдромом, включающий янтарную кислоту, йодинол, левамизол при следующем соотношении компонентов на 1000 мл водного раствора: янтарная кислота - 10,0 г, йодинол - 250 мл, левамизол - 10,0 г. 2 н.п. ф-лы, 6 табл., 3 пр.

СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ГИПЕРТИРЕОЗА У КОШАЧЬИХ

Группа изобретений относится к области ветеринарии и предназначена для лечения гипертиреоза кошачьих. Заявлены способ, композиция, набор и применение селена для лечения гипертиреоза у кошачьих. Способ включает скармливание кошачьему композиции, включающей от около 0,1 до менее чем около 1 мг/кг селена по сухому веществу в сочетании с введением кошачьему антитиреоидного агента. Заявленная композиция включает от около 0,1 до менее чем около 1 мг/кг селена по сухому веществу и терапевтически эффективное количество антитиреоидного агента. Набор включает композицию с содержанием от около 0,1 до менее чем около 1 мг/кг селена по сухому веществу и антитиреоидный агент и инструкции. Заявлено также применение селена для получения заявленной композиции. Группа изобретений высокоэффективна для лечения гипертиреоза кошачьих. 5 табл., 3 пр.

БИОЦИДНЫЕ КАПСУЛЫ, СОДЕРЖАЩИЙ ИХ ПРЕПАРАТ И ТАМПОН, СОДЕРЖАЩИЙ ПРЕПАРАТ

Группа изобретений относится к области медицины. Биоцидная капсула для лечения и диагностики влагалища для применения в биоцидном препарате, в которой, по меньшей мере, один активный ингредиент заключен в капсулы со стенкой, не растворимой или минимально растворимой в водном окружении с диапазоном рН ниже порогового значения рН, но растворимой в диапазоне рН выше порогового значения рН, в которой пороговое значение рН находится между 4,6 и 6,0 и, по меньшей мере, одно из стенки и содержимого содержит индикаторное вещество, подходящее для цветовой индикации. Тампон содержит биоцидный препарат, который в случае влагалищного тампона включает гигроскопический цилиндр (1), предпочтительно набухающий в поперечнике под действием жидкости, имеющий на внутреннем конце более длинный задний выступ (2), вставляемый до заднего свода влагалища и брюшинный выступ (3), более короткий, чем задний выступ, а между ними находится седловина (4), принимающая влагалищную часть шейки матки. Изобретение позволяет ...

Способ получения нанокапсул солей металлов в агар-агаре

Изобретение относится к области нанотехнологии, в частности к фармацевтике, и раскрывает способ получения нанокапсул солей металлов в агар-агаре. Способ характеризуется тем, что 100 мг соли металла (иодид калия, карбонат магния, цинка или кальция, хлорид кальция) диспергируют в суспензию 100 или 300 мг агар-агара в бензоле в присутствии 0,01 г препарата Е472с в качестве поверхностно-активного вещества при перемешивании 1200 об/мин, далее приливают 5 мл хлороформа, при этом мольное соотношение ядро:оболочка составляет 1:1 или 1:3, затем полученную суспензию отфильтровывают и сушат при комнатной температуре. Изобретение обеспечивает упрощение и ускорение процесса получения нанокапсул и увеличение выхода по массе. 11 пр., 3 ил.

СПОСОБ ПОВЫШЕНИЯ УСТОЙЧИВОСТИ ОРГАНИЗМА К ВРЕДНОМУ ДЕЙСТВИЮ ТОКСИЧЕСКОЙ КОМБИНАЦИИ, ЗАГРЯЗНЯЮЩЕЙ ВОЗДУХ РАБОЧЕЙ ЗОНЫ И ОКРУЖАЮЩУЮ АТМОСФЕРУ В СВЯЗИ С ДЕЯТЕЛЬНОСТЬЮ ПРОИЗВОДСТВА ЧЕРНОВОЙ МЕДИ

Изобретение относится к медицине, а именно к токсикологии, и может быть использовано для снижения неблагоприятных эффектов комбинированного действия на организм неорганических соединений меди, цинка, свинца, мышьяка и кадмия в группах риска, охватывающих как рабочих, которые подвергаются такому воздействию в условиях производства черновой меди, так и население территорий, находящихся под воздействием этого производства. Для этого лица из группы повышенного риска принимают биопрофилактический комплекс, включающий глютаминат натрия, глицин, цистеин в метаболически активной форме N-ацетилцистеина, яблочный пектин, селен, йод, кальций, железо, препарат рыбьего жира, богатый полиненасыщенными жирными кислотами класса омега-3, а также витамины А, В1, С, Д3 и Е, причем прием этого комплекса осуществляют повторными 4-недельными курсами 2 раза в год в дозах, обеспечивающих получение в день 300 мг глицина, 600 мг цистеина, 4 г глютаминовой кислоты, 25 мл рыбьего жира с содержанием 12-15% полиненасыщенных ...

СПОСОБ ЛЕЧЕНИЯ ГИПОТИРЕОЗА У КРУПНОГО РОГАТОГО СКОТА

Изобретение относится к области ветеринарии и касается лечения гипотиреоза крупного рогатого скота. Для этого к основному рациону добавляют йодказеин в количестве 1480 мг/гол. 1 раз в день в течение месяца и скармливают в течение одного месяца один раз в день. Способ позволяет улучшить общее состояние, гематологические и биохимические показатели и продуктивность животных. 1 з.п. ф-лы, 2 табл.

Раствор для декальцинации при лечении заболеваний опорно-двигательного аппарата

Изобретение относится к медицине, а именно к фармацевтике, и может быть использовано при лечении воспалительных и дегенеративных заболеваний опорно-двигательного аппарата, вызванных отложением кальция. Средство содержит цинка сульфат, калия йодид, магния сульфат, диметилсульфоксид и воду при определенном соотношении компонентов. Использование изобретения повышает декальцинирующее действие средства. 1 табл., 3 пр.

УСТРОЙСТВО АППЛИКАЦИИ ЖИДКОСТИ И СПОСОБ

Группа изобретений относится к области медицины, а именно к подготовке пациентов к различным медицинским процедурам, например к хирургической операции, включающей в себя аппликацию раствора (или жидкости) для местного применения, например антисептического раствора, для дезинфекции целевого участка проведения медицинских процедур. Аппликаторное устройство для аппликации местного антисептика на кожу содержит ручку, имеющую проксимальный конец и дистальный конец; основание, соединенное с проксимальным концом ручки; гидрофильную пену, соединенную с основанием, и, по крайней мере, один абразивный слой, связанный с гидрофильной пеной. Гидрофильная пена предназначена для распределения местного антисептика на кожу. Абразивный слой и гидрофильная пена совместно пригодны для аппликации местного антисептика на кожу. Аппликаторная система в свою очередь содержит аппликаторное устройство, включающее в том числе гидрофильную пену, предназначенную для впитывания местного антисептика; и футляр, предназначенный ...

СПОСОБ ПОВЫШЕНИЯ ПРИВЕСОВ ПРИ ОДНОВРЕМЕННОЙ ПРОФИЛАКТИКЕ ОКСИДАТИВНОГО СТРЕССА У ЦЫПЛЯТ-БРОЙЛЕРОВ

Изобретение относится к области птицеводства и ветеринарии и может быть использовано как способ повышения привесов цыплят-бройлеров, профилактики оксидативного стресса и, как следствие, увеличения их продуктивности. Способ включает пероральное введение птицам с 3-суточного возраста кормовой добавки «Абиовит» с водой для поения в дозе 1 мл/л воды каждые 5 суток до 33-суточного возраста и кормовой добавки «Абиопептид» с водой для поения в дозе 1 мл/л воды через день до 35-суточного возраста. Осуществление данного изобретения обеспечивает повышение привесов и профилактику оксидативного стресса у цыплят-бройлеров. 2 табл.

НОВЫЙ АНТГЕЛЬМИНТНЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ОСТЕРТАГИОЗА КРУПНОГО И МЕЛКОГО РОГАТОГО СКОТА

Изобретение относится к области ветеринарии и предназначено для лечения и профилактики остертагиоза крупного и мелкого рогатого скота. Антгельминтный препарат для лечения и профилактики остертагиоза крупного и мелкого рогатого скота включает альбендазол 10% и дополнительно содержит фенбендазол, пропиленгликоль, йодированную поваренную соль, стрептоцид растворимый, норсульфазол растворимый, окситетрациклин, фруктозу, 10% суспензию свежей гашеной извести и водную 20% суспензию бентонита при следующем соотношении компонентов мас. %: альбендазол 10% - 5, фенбендазол - 10, пропиленгликоль - 20, йодированная поваренная соль - 3, стрептоцид растворимый - 0,2, норсульфазол растворимый - 0,2, окситетрациклин - 0,1, фруктоза - 1,5, 10% суспензия свежей гашеной извести - 10, водная 20% суспензия бентонита - 50. Заявленное изобретение высокоэффективно для лечения и профилактики остертагиоза крупного и мелкого рогатого скота. 3 табл., 3 пр.

Способ оперативного лечения эмпиемы плевры с бронхоплевральным свищом

Изобретение относится к медицине, а именно, к торакальной хирургии. Проводят торакоскопию для выявления локализации наружного отверстия бронхоплеврального свища. Затем осуществляют антисептическую обработку плевральной полости. Под контролем видеокамеры производят инъекции клеевой композиции в легочную ткань, окружающую свищевой ход. При этом в качестве клеевой композиции используют концентрированный мономер фибрина на основе собственной плазмы крови пациента в растворе карбонатно-бикарбонатного буфера-pH10. Инъекции клеевой композиции в легочную ткань осуществляют на 1-1,5 см глубже висцеральной плевры. Способ позволяет повысить эффективность обструкции хода бронхоплеврального свища, обеспечить надежный аэростаз, создать условия для купирования воспаления, обеспечить грануляционные процессы, улучшить эффективность пролиферации и репарации клеток повреждённых тканей по глубине свищевого хода. 1 з.п. ф-лы, 2 ил., 1 пр.

СПОСОБ СОСТАВЛЕНИЯ ПЕРСОНИФИЦИРОВАННОЙ ПРОГРАММЫ ПРЕГРАВИДАРНОЙ ПОДГОТОВКИ ПАЦИЕНТОК С БЕСПЛОДИЕМ И ОЖИРЕНИЕМ К ВСПОМОГАТЕЛЬНЫМ РЕПРОДУКТИВНЫМ ТЕХНОЛОГИЯМ

Изобретение относится к медицине, а именно к акушерству и гинекологии и может быть использовано для персонифицированной программы прегравидарной подготовки пациенток с бесплодием и ожирением к вспомогательным репродуктивным технологиям (ВРТ). Проводят фиксацию веса. Определяют индекс массы тела (ИМТ). Проводят биохимический анализ крови с определением уровня гомоцистеина, витамина Д (25-OH-D), ферритина, гликированного гемоглобина (HbA1c). Продолжительность персонифицированной программы прегравидарной подготовки составляет от 3 до 6 месяцев. Осуществляют сопровождение врача по коррекции питания и образа жизни и прием медикаментов и нутриентов. Способ обеспечивает повышение эффективности программ ВРТ, а также улучшение перинатальных исходов в группе пациенток с ожирением. 2 пр.

Способ устранения и профилактики йододефицитного состояния у человека

Изобретение относится к медицине, а именно к терапии и эндокринологии, и может быть использовано для профилактики йододефицитного состояния у человека. Для этого на кожу наносят спиртовой раствора йода ежедневно с формированием линий посредством устройства с возможностью отдачи 5%-ого спиртового раствора йода с интенсивностью 0,04-0,05 г/м. При этом площадь ежедневного нанесения составляет 10,5 – 25 см2. Ежедневное нанесение раствора осуществляют в течение одной недели. Изобретение обеспечивает эффективную и безопасную профилактику йододефицитного состояния с возможностью исключения случайных ожогов кожи спиртовым раствором йода. 3 пр.

Средство для лечения и профилактики послеродового эндометрита и цервицита у коров

Изобретение относится к ветеринарной медицине, в частности к средству для лечения и профилактики послеродового эндометрита и цервицита у коров. Средство содержит компоненты в следующим соотношении, мас.%: клевер красный - 25-30; ортилия однобокая - 10-15; ромашка аптечная - 5-10; крапива двудомная - 5-10; тысячелистник обыкновенный - 5-10; раствор люголя с глицерином - 15-20; кокосовое масло - 5-10; 40% водно-спиртовой раствор - до 100%. Вышеописанное средство позволяет проводить лечение и профилактику послеродового эндометрита и цервицита у коров при терапевтической эффективности 100%. 3 табл., 1 пр.

СПОСОБ ЛЕЧЕНИЯ И ГРУППОВОЙ ПРОФИЛАКТИКИ АССОЦИИРОВАННЫХ ТРЕМАТОДОЗОВ ОВЕЦ

Изобретение относиться к ветеринарной медицине, в частности к области ветеринарной паразитологии. Предложенный способ лечения и профилактики ассоциированных трематодозов мелкого рогатого скота заключается в том, что животным задают групповым методом однократно состав, включающий Фаскоцид гранулы, микронизированный порошок бентонита размером частиц 25-60 микрон, полиоксидоний порошок, хелат меди, хлористый кобальт и йодированную поваренную соль с комбикормом при следующем соотношении компонентов, г/гол.: Фаскоцид гранулы в дозе - 3,75, микронизированный порошок бентонита размером частиц 25-60 микрон - 75,0, полиоксидоний порошок - 0,125, хелат меди - 0,375, хлористый кобальт - 0,25, йодированная поваренная соль - 38,0, сухой комбикорм - 200,0. Вышеописанный способ обеспечивает высокую антигельминтную эффективность профилактики и лечения, облегчение труда при введении препарата, сокращение времени проведения обработок, повышает продуктивность животных, исключает технологический стресс. 8 ...

СПОСОБ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ГЛОМЕРУЛЯРНОГО И ТУБУЛОИНТЕРСТИЦИАЛЬНОГО ЗАБОЛЕВАНИЙ ПОЧЕК У ДЕТЕЙ, АССОЦИИРОВАННЫХ С ТОКСИЧЕСКИМ ДЕЙСТВИЕМ КАДМИЯ, СВИНЦА, ХРОМА И ФЕНОЛА ТЕХНОГЕННОГО ПРОИСХОЖДЕНИЯ

Изобретение относится к медицине и предназначено для лечения и профилактики гломерулярного и тубулоинтерстициального заболеваний почек у детей, проживающих в зоне влияния промышленных предприятий в условиях загрязнения атмосферного воздуха кадмием, свинцом, хромом и фенолом. На первом этапе назначают прием поливитаминов с микро- и макроэлементами из серии «Витрум» перорально курсом 21 день по 1 таблетке 1 раз в день после еды: «Витрум-кидс» - дети в возрасте 7 лет; «Витрум-юниор» - дети старше 7 лет и препарата «Димефосфон» перорально курсом 10 дней: детям в возрасте 7-8 лет в разовой дозе 10 мл 3 раза в день или в суточной дозе 30-50 мг/кг; детям в возрасте старше 8 лет в разовой дозе 15 мл 3 раза в день или в суточной дозе 30-50 мг/кг. На втором этапе назначают «Ксидифон» курсом 10 дней для детей в возрасте 7-10 лет - по 1 десертной ложке 0,2 г 2-3 раза в день; а для детей старше 10 лет - по 1 столовой ложке 0,3 г 2-3 раза в день. Способ позволяет повысить эффективность лечения токсических ...

СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ НЕХВАТКОЙ ЙОДА

Изобретение относится к применению крахмала в качестве вещества, образующего комплекс с иодом, для поучения сухих фармацевтических композиций, применимых в виде капсул или таблеток. Спиральная структура молекулы амилазы и ее способность образовывать комплекс с йодом делает крахмал (амилазу) требуемым носителем при введении йода (Jz) в составе сухой порошковой композиций, применимой в виде капсул или таблеток. Изобретение заключается в применении указанного комплекса при лечении или предотвращении болезней, вызванных недостатком йода, включая дисплазию молочной железы, рак молочной железы, эндометриоз, предменструальный синдром. Сухие композиции йода превосходят известные водные растворы йода по удобству приема. 2 з.п.ф-лы, 1 ил., 1 табл.

СПОСОБ ЛЕЧЕНИЯ ИНФЕКЦИОННЫХ ЗАБОЛЕВАНИЙ ДИСТАЛЬНОГО ОТДЕЛА КОНЕЧНОСТЕЙ КРУПНОГО РОГАТОГО СКОТА

Изобретение относится к области ветеринарии и предназначено для лечения инфекционных заболеваний дистального отдела конечностей крупного рогатого скота. В качестве лечебного препарата используют йодпротектин в разведении дистиллированной водой 1:5. Наносят тонким слоем на пораженную поверхность конечностей с наложением повязки 2-3 раза с интервалом 4-5 дней. Изобретение обеспечивает высокий терапевтический эффект. 1 табл., 1 пр.

СПОСОБ ВОССТАНОВЛЕНИЯ И УКРЕПЛЕНИЯ ЭНДОЭКОЛОГИЧЕСКОЙ ЗАЩИТЫ ОРГАНИЗМА ЧЕЛОВЕКА

Изобретение относится к области медицины, а именно к способам немедикаментозного оздоровления организма человека, укрепления всех его защитных функций и систем. Способ восстановления и укрепления эндоэкологической защиты организма человека в течение тринадцатидневного курса заключается в том, что предварительно проводят опрос, замеры и компьютерную диагностику состояния здоровья пациента, определяют его исходное физиологическое и психологическое состояние, выявляют биологический возраст, жизненную емкость легких, адаптационный потенциал, уровень глюкозы в крови. Весь курс оздоровления проводят на фоне разгрузочного питания с использованием каши кичри, рисовой и гороховой каш, травяных чаев и программы дегельминтизации. Восстановление и укрепление эндоэкологической защиты организма человека осуществляют в четыре этапа. Первый этап включает подготовку кишечника с помощью масел, клизм с травяным очистительным составом и микроклизм с синим йодом, а также нормализацию флоры растительными средствами ...

СПОСОБ ВИЗУАЛИЗАЦИИ СОСУДИСТОГО РУСЛА ПЛАЦЕНТЫ С ИСПОЛЬЗОВАНИЕМ МУЛЬТИСПИРАЛЬНОЙ КОМПЬЮТЕРНОЙ ТОМОГРАФИИ-АНГИОГРАФИИ

Изобретение относится к медицине, а именно к акушерству, и может быть использовано для визуализации сосудистого русла плаценты с оценкой пространственной конфигурации сосудов. Для этого, после родоразрешения, последовательно проводят пункцию сосудов пуповины плаценты инъекционной иглой с использованием отдельных шприцев. Затем вводят водный раствор контрастного вещества «Ультравист» в дозе 60 мл при доношенной беременности и в дозе 20-40 мл при недоношенной беременности. Через 10-15 мин после введения контрастного препарата выполняют мультиспиральную компьютерную томографию с толщиной среза 0,5 мм, с последующим построением трехмерных и мультипланарных реконструкций сосудистого русла плаценты. Изобретение обеспечивает визуализацию артериальной и венозной архитектоники плаценты без трудоемкой подготовки перед исследованием и может использоваться в клинической практике. 5 ил., 3 пр.

Способ повышения устойчивости организма к комбинированному вредному действию свинца и кадмия

Изобретение относится к медицине, в частности к способу повышения устойчивости организма к развитию многосторонних вредных эффектов комбинированного действия на него свинца и кадмия в ионной форме. Способ заключается в том, что лицам, относящимся к группе риска указанного действия, назначают комплекс биологически активных препаратов, включающий глютаминат натрия, цистеин в метаболически активной форме N-ацетилцистеина, яблочный пектин, селен, йод, кальций, железо, магний, препарат рыбьего жира, богатый полиненасыщенными жирными кислотами класса омега-3, кверцетин в виде рутина, витамины А, С, Е и D3, витамины группы В1, В2, В6. Лица группы риска принимают препараты этого комплекса повторными 4-6-недельными курсами 1-2 раза в год в определенных дозах. Способ обеспечивает снижение вредных эффектов токсического, кардиотоксического и генотоксического комбинированного действия соединений кадмия и свинца в ионной форме на организм. 4 ил., 4 табл.

СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ГИПЕРТИРЕОЗА У КОШАЧЬИХ

... 1. Способ лечения гипертиреоза у кошачьих, включающий введение кошачьему антитиреоидного агента совместно со скармливанием кошачьему композиции, включающей от около 0,1 до менее чем около 1 мг/кг йода по сухому веществу. ! 2. Способ по п.1, где кошачьему вводят терапевтически эффективное количество антитиреоидного агента. ! 3. Способ по п.1, где антитиреоидный агент включает метимазол. ! 4. Способ по п.1, где антитиреоидный агент включает тионамид. ! 5. Способ по п.4, где тионамид выбран из группы, состоящей из метимазола, пропилтиоурацила и карбимазола. ! 6. Способ по п.1, где композиция включает от около 0,1 до около 0,5 мг/кг йода. ! 7. Способ по п.6, где композиция включает от около 0,1 до около 0,3 мг/кг йода. ! 8. Способ по п.1, где композиция дополнительно включает от около 0,1 до около 1 мг/кг селена по сухому веществу. ! 9. Способ по п.8, где композиция дополнительно включает от около 0,1 до около 0,8 мг/кг селена по сухому веществу. ! 10. Способ по п.9, где композиция дополнительно ...

ЛЕЧЕНИЕ СЕРДЕЧНОГО ПРИСТУПА И ИШЕМИЧЕСКОГО ПОВРЕЖДЕНИЯ СОЕДИНЕНИЯМИ ГАЛОГЕНА

НОВАЯ СИНЕРГИЧЕСКАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ТОПИЧЕСКОГО НАНЕСЕНИЯ

... 1. Новая синергическая фармацевтическая композиция для получения топического состава для профилактики и лечения ран, ожоговых ран, кожных трансплантатов, пролежней и диабетических язв стоп, содержащая митогенный белок, одно или более бактерицидных средств и один или более бактериостатических средств, причем указанные топические составы также содержат один или более других ингредиентов.2. Новая синергическая фармацевтическая композиция для получения топического состава по п.1, где указанный митогенный белок представляет собой один или более фактор роста, выбранный из группы, состоящей из рекомбинантного человеческого эпидермального фактора роста (rh-EGF), происходящего из тромбоцитов фактора роста AA и/или BB (rh-PDGF-AA и/или BB) или любой другой фактор роста.3. Новая синергическая фармацевтическая композиция для получения топического состава по п.1, где указанные бактерицидные и бактериостатические средства выбраны из группы, состоящей из бацитрацина, сульфадиазина серебра (SSD), нитрофуразона ...

ИСПОЛЬЗОВАНИЕ ИЗООСМОТИЧЕСКИХ ИОННЫХ РАСТВОРОВ НА ОСНОВЕ МОРСКОЙ ВОДЫ ДЛЯ ПРОФИЛАКТИКИ ОСЛОЖНЕНИЙ ПРОСТУДЫ И ГРИППА

... 1. Применение изоосмотического ионного раствора на основе морской воды для изготовления медицинского устройства для введения указанного раствора в виде назального спрея или аэрозоля пациентам на стадии ремиссии насморка или гриппоподобного синдрома или пациентам, страдающим от насморка или гриппоподобного синдрома, с целью профилактики и/или лечения осложнений от насморка или гриппоподобного синдрома. ! 2. Применение по п.1, отличающееся тем, что изоосмотический ионный раствор на основе морской воды имеет следующие характеристики: ! рН, равный 7,8-8,4; ! содержание сухого вещества, равное от 1 до 2% по весу; ! осмолярность, равную 250-350 мОсм/кг, предпочтительно равную 305-315 мОсм/кг, ! и содержит следующие основные компоненты: ! 500-2600 мг/л натрия (Na); ! 40-6500 мг/л калия (Ка); ! 5800-6000 мг/л ионов хлора (Cl); ! 20-400 мг/л кальция (Са); ! 50-1500 мг/л магния (Mg). ! 3. Применение по п.1 или 2, отличающееся тем, что изоосмотический ионный раствор на основе морской воды имеет следующие ...

Состав для стимуляции метаболических процессов, системы иммунитета, профилактики заболеваний диареей

... 1. Состав для стимуляции метаболических процессов, системы иммунитета, профилактики заболеваний диареей, включающий янтарную кислоту, йодинол, отличающийся тем, что дополнительно содержит АСД второй фракции при следующем соотношении компонентов на 1000 мл водного раствора:Янтарная кислота - 10,0 гЙодинол - 250 млАСД второй фракции - 40 мл.2. Состав для стимуляции метаболических процессов, системы иммунитета, профилактики заболеваний диареей, включающий янтарную кислоту, йодинол, отличающийся тем, что дополнительно содержит левамизол при следующем соотношении компонентов на 1000 мл водного раствора:Янтарная кислота - 10,0 гЙодинол - 250 млЛевамизол - 10,0 г.

Способ получения препарата на основе альгината натрия и N-винилпирролидона, обогащенного активным йодом

Изобретение относится к области химико-фармацевтической промышленности, а именно к способу получения препарата на основе альгината натрия и N-винилпирролидона, обогащенного активным йодом. Способ получения препарата на основе альгината натрия и N-винилпирролидона, обогащенного активным йодом, включающий растворение йода в растворе йодистого калия в стерильной воде для инъекций, последующее добавление полисахарида, отличающийся тем, что растворяют 5-6 г йода в 30 г 10 мас.%-ного раствора йодида калия, приготовленного на стерильной воде для инъекций, после чего при постоянном перемешивании со скоростью 250 об/мин для получения вязкого раствора вносят 2-3 г, а для получения геля - 4-5 г привитого сополимера альгината натрия с соотношением остатков β-D-маннуроновой (М-звенья) и α-L-гулуроновой (G-звенья) кислот М-звенья/G-звенья=1,56 и вязкостью 1%-ного масс. водного раствора при 25°С, равной 4-12 cps, и N-винилпирролидона, с содержанием в сополимере привитых цепей N-винилпирролидона с молекулярной ...

Immunotrophische Preparation zur Behandlung von tonsillärer Hypertrophie

ANTITUMOR AGENT

Dietary supplement

A composition or dietary supplement for a pet is provided. The composition comprises: a supplement for joint health, such as glucosamine, methylsulfonlymethane, chondroitin, pine bark extract, or omega 3 fatty acids; a supplement for digestive health such as digestive enzymes; a probiotic such as Lactobacillus spp. or Enterococcus faecium; a prebiotic such as fibre or chicory extract; at least one vitamin and at least one mineral. The composition may also comprise cardiovascular health supplements such as L-arginine; weight loss supplements such as L-carnitine L-tartrate; energy supplements such as L-citrulline DL-malate; urinary or kidney tract health supplements such as taurine; liver health supplements such as milk thistle; and bone health supplements such as calcium. Also described are methods of treatment using the composition.

Drug composition and its use in therapy

Medicinal preparations with enteric protection

A solid product for oral administration consists of a medicinal substance incorporated in or coated with sodium carboxymethyl cellulose to form a mass which is enveloped in a surface film of acid carboxymethyl cellulose. The medicinal substance, sodium carboxymethyl cellulose and water are mixed to form a suitable mass e.g. pill or tablet, dried and immersed in an acid of pH 0.4 to 2.5 to form a surface film of the acid carboxymethyl cellulose. The mass is dried and unreacted acid thereby removed. Hydrochloric acid is preferred because of its volatility; sulphuric or phosphoric acid may be used. Optional additions are fillers such as bentonite, magnesium aluminium silicate, kaolin and china clay. Specified medicinal substances are colloidal iodine, specific examples of which are given, hormones and penicillin. Specification 665,073 is referred to.

Stabilised tablets containing iodide and iodate

This invention describes a stabilized an oral pharmaceutical composition comprised of iodide and iodate as the active agents in the presence of other pharmaceutical excipients. The composition contains a pH control agent to limit the pH to between 7 and 12.

Compositions for the topical treatment of eczema, psoriasis and the like

Stabilized oral pharmaceutical composition containing iodide and iodate and method

This invention describes a stabilized oral pharmaceutical composition comprised of iodide and iodate as the active agents in the presence of other pharmaceutical excipients and method for preparing these stabilized compositions.

Compositions for topical treatment

Labelling of dry powder formulations for inhalation

Multi-component bolus

A bolus for oral administration to an animal, the bolus comprising at least one beneficial substance to be delivered to the animal, the bolus comprising two components which are adhered together by a water-soluble adhesive or sealant, such that the two components are separable in vivo; wherein at least one of the aforesaid components is frangible in vivo, the frangible component 2 being initially stabilised by the adherence thereto of the other of the aforesaid components (4), such that separation of the two components facilitates the breakage of the frangible component. Preferably, the frangible component comprises a relatively thin zone or region 20. Preferably, one component comprises a cobalt-containing compound and the other comprises a selenium-containing compound. Also disclosed is a method of making said bolus, the method comprising the steps of forming the first and second components, adhering them together using a water-soluble adhesive; wherein at least one of said components ...

X-ray contrast media

Injectable X-ray contrast media comprise an aqueous solution of at least one sodium salt of an iodinated organic acid, which solution contains calcium and/or magnesium ions. Specified contrast agents are sodium metrizoate; diatrizoate; iothalamate; 3, 5-dipropionylamido-2, 4, 6-triiodobenzoate; N, N1-di(hydroxyethyl)-3, 5-diacetamido-2, 4, 6-triiodobenzoate; 3-acetamido-2, 4, 6-triiodobenzoate; 3-acetamido-5-propionamido-2, 4, 6-triiodobenzoate; and iodo-methane sulphonate. Calcium and magnesium ions may be added as X-ray-in-active salts, such as the chlorides; or as salts of radio-opaque iodinated organic acids. Alternatively, aqueous solutions of these acids may be neutralized with mixed sodium and calcium and/or magnesium salts. Other substances present may be chelating agents (ethylene diamine and tetra-acetate) and buffers (sodium biphosphate). The Ca and Mg ions are said to improve the physiological compatibility of the contrast media.

Supplement preparation.

Supplement preparation

Supplement preparation.

Cream SAGINA.

Lotion “ETAA”.

Method of treatment of the infectious bursite (the disease of Gumboro).

Supplement preparation.

Supplement preparation.

AUXILIARY COMPOSITION WITH CARTILAGE AND SILVER

WATER IN OIL EMULSIONS CONTAINING OIL-SOLUBLE VINYL OF POLYMERS WITH ACIDI GROUPS IN SEITENKETTEN, COMPOSITIONS AND METHODS

USE OF PVP-IOD LIPOSOMEN FOR THE TREATMENT OF ATOPI DERMATITIS

TRACE ELEMENTS

PROCEDURE FOR THE PRODUCTION OF A DISINFECTION OF MEANS

AND PROCEDURE FOR THEIR PRODUCTION CONTAINS STABILIZED ORAL ONES PHARMACEUTICAL COMPOSITION, THE IODIDE AND JODAT

CHAIR MARKER

PROCEDURE FOR THE PRODUCTION OF A WUNDHEILMITTELS

LIPID/JODSOLE KOMBINATIONSPRÄPARAT ZUR BEHANDLUNG DES TROCKENEN AUGES

Es wird eine Kombination zweier Wirksubstanzen : einer 20%-igen Öl-in-Wasser - Emulsion und einer natürlichen Jodsole-Lösung beschrieben,welche im Verhältnis 1 : 1 gemischt werden. Zur Behandlung des Trockenen Auges wird dieses Kombinationspräparat (10%-ige Lipid-Jodsole-Emulsion) durch einen leistungsstarken Zerstäuber (Kompressor) feinst zerstäubt gegen die Augenoberfläche gesprüht.

USE OF THE HYDRIODIC ACID AS APHRODISIAC

STABILIZED PVP-I SOLUTIONS

PROCEDURE FOR THE PRODUCTION OF JODOPHOR POWDERS.

GERM-KILLING DETERGENZ IODINE COMPOSITIONS WITH REDUCED ONE DETERGENZGEHALT

USES HYDROPHILIC POLYMER MIXTURES, TO THE PREVENTION OF SKIN INFECTIONS WITH COWS

IMMUNOTROPHI PREPARATION FOR THE TREATMENT OF TONSILLÄRE HYPERTROPHIE

JODIERTE PROTEINS FOR THE PREVENTION OF LACK OF IODINE CONDITIONS

A ANTIOXYRIERUNGSMITTEL ON BASIS FROM PLANT EXTRACTS TO THE TREATMENT OF CYCLE AND FAT CRAZE PROBLEMS

GERM-KILLING, DOWN PH IODINE COMPOSITIONS WITH INCREASED STABILITY

WATER IN OIL EMULSIONS CONTAINING OIL-SOLUBLE VINYL OF POLYMERS WITH ACIDI GROUPS IN SEITENKETTEN, COMPOSITIONS AND METHODS

WATER IN OIL EMULSIONS CONTAINING OIL-SOLUBLE VINYL OF POLYMERS WITH ACIDI GROUPS IN SEITENKETTEN, COMPOSITIONS AND METHODS

WATER IN OIL EMULSIONS CONTAINING OIL-SOLUBLE VINYL OF POLYMERS WITH ACIDI GROUPS IN SEITENKETTEN, COMPOSITIONS AND METHODS

WATER IN OIL EMULSIONS CONTAINING OIL-SOLUBLE VINYL OF POLYMERS WITH ACIDI GROUPS IN SEITENKETTEN, COMPOSITIONS AND METHODS

WATER IN OIL EMULSIONS CONTAINING OIL-SOLUBLE VINYL OF POLYMERS WITH ACIDI GROUPS IN SEITENKETTEN, COMPOSITIONS AND METHODS

WATER IN OIL EMULSIONS CONTAINING OIL-SOLUBLE VINYL OF POLYMERS WITH ACIDI GROUPS IN SEITENKETTEN, COMPOSITIONS AND METHODS

WATER IN OIL EMULSIONS CONTAINING OIL-SOLUBLE VINYL OF POLYMERS WITH ACIDI GROUPS IN SEITENKETTEN, COMPOSITIONS AND METHODS

WATER IN OIL EMULSIONS CONTAINING OIL-SOLUBLE VINYL OF POLYMERS WITH ACIDI GROUPS IN SEITENKETTEN, COMPOSITIONS AND METHODS

WATER IN OIL EMULSIONS CONTAINING OIL-SOLUBLE VINYL OF POLYMERS WITH ACIDI GROUPS IN SEITENKETTEN, COMPOSITIONS AND METHODS

IODIDE FREE IODOPHOR

Treatment of avascular or hypovascular micro-tumors

ANTISEPTIC COMPOSITION

Supplement preparation

Ophthalmic compositions comprising povidone-iodine

A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post- LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection.and inflammation in the post-operative ophthalmic patient.

COMPOSITION FOR RESTORING DAMAGED SKIN

Theobromine in combination with an expectorant or a mucolytic for use in therapy

An agent comprises theobromine and an expectorant, or an agent comprises theobromine and a mucolytic. The agents of the invention may be used as a combined preparation for simultaneous, sequential or separate use in the therapy of cough.

An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems

Stable compositions of uncomplexed iodine and methods of use

The present invention is directed to a composition in solution (often, an aqueous solution) which comprises a combination of molecular iodine (l ...

Iodophor composition with improved stability in the presence of organic material

The invention is concerned with a pharmaceutical and industrial iodophor preparation, its synthesis and potential applications. The compound has predictable antimicrobial activities. Furthermore, this iodophor is much more stable in the presence of organic material than traditional iodophors. The compositions release free iodine when in solution, which provides the antimicrobial activity.

Pharmaceutical product

Strontium based compositions and formulations for pain, pruritus, and inflammation

STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied.

Antimicrobial compositions and methods for their production

This invention relates to a method for preparing compositions for preventing or treating microbial infections, compositions suitable for use in such treatments and methods for treatment or prevention of infections. One such composition finds particular use in treating mastitis in ruminants. The composition is administered into the udder of an animal as a highly effective treatment for mastitis, or as a prophylactic therapy, by means of an intra-mammary infusion. The milk produced by the animal, during treatment using the composition and method of the invention, is free of residues, such as antibiotics, antimicrobial agents or antimicrobial proteins, which could affect its suitability for drinking or in the production of milk products, such as cheese or yoghurt. The compositions and methods are also useful in treating and preventing lung infections; and infections in bums and wounds; and other infections caused by biofilms. The compositions may also be used on medical devices to prevent ...

Stabilized oral pharmaceutical composition containing iodide and iodate and method

Treatment of macrophage-related disorders

The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.

Virucide drug containing iodine

PROCESS FOR THE PEPARATION OF IODOPHOR COMPOUNDS AND METHODS FOR STABILIZING IODOPHOR PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

COMPOSITIONS FOR IMPROVING BREAST HEALTH IN WOMEN

... ²²²Disclosed are compositions and corresponding methods for treating fibrocystic ²breast disease or other breast-related disease or condition. The compositions ²comprise, per serving or dose, from zero to about 400 ~g selenium, from about ²100 mg to about 6000 mg gamma linolenic acid, and about 0.15mg to about 5 mg ²iodine, with nutritional embodiments further comprising one or more of ²protein, fat, carbohydrate, vitamins, and minerals and providing from about 50 ²to about 1000 kcal of energy per severing or dose. Also disclosed are in-vitro ²studies showing that certain combinations of gamma linolenic acid, iodine, ²and/or selenium may 1) inhibit breast cancer or fibrocystic cell ²proliferation, 2) reinforce the function of tight junctions of endothelial ²cells and of mammary epithelial cells in estrogen-sensitive conditions, and 3) ²reduce the risk of vascular invasion by breast cancer cells.² ...

HYDROGEL FORMULATION COMPRISING OXIDATIVE REDUCTIVE POTENTIAL WATER

The present invention relates to a hydrogel formulation containing an oxidative reduction potential (ORP) water solution and a gelling agent. The invention further provides a method for treating or preventing a condition in a patient comprising topically administering to a patient a therapeutically effective amount of a hydrogel formulation comprising an oxidative reductive potential solution and a gelling agent. A method for promoting wound healing in a patient is also provided.

MANUFACTURING PROCESS FOR A SLIMMING HEALTH PRODUCT

A slimming lotion serves without chemical reaction or muscular activity to obtain by simple local application a controlled cooling lasting for a long time in order to accelerate cellular vibrations by activation of the circulation of the blood so that the fatty cells, because of the intensity of this reactionary circulation, draw more oxygen from the arterial capillary blood vessels, thus more carbon dioxide gas to the venous capillary blood vessels, thus causing their elimination. A process for preparation of the lotion comprises the mixing of ethyl alcohol, distilled water, crystallised camphor, menthol Codex Registered Trade Mark, potassium iodide, sodium chloride, calcium chloride, and perfume essence.

FLUID APPLICATION DEVICE AND METHOD

Use of a synergistic combination of hypothiocyanite and/or hypohalite ions and lactoferrin for preparing a treatment for cystic fibrosis

The invention relates to the use of a synergistic combination of at least one ion selected from the group including hypothiocyanites and/or hypohalites and of lactoferrin for preparing a pharmaceutical composition for treating cystic fibrosis. In one embodiment, the lactoferrin is one having a purity higher than 95% and substantially free of lipopolysaccharides, endotoxins, and angiogenins, and having an iron saturation level higher than 15%.

Trace Elements

The inventions discloses a trace element solution, which comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

Compositions, kits and methods for nutrition supplementation

The present invention relates to compositions, kits and methods for the administration of various vitamin, mineral and nutrient compositions, and in a specific embodiment, the compositions, kits and methods may utilize or include twelve carbon chain fatty acids and/or twelve carbon chain acylglycerols, vitamin D, iodine, vitamin B1, vitamin B6, vitamin B12, vitamin B2, vitamin B9, vitamin B3, vitamin E, vitamin A, vitamin C, iron, zinc, copper, magnesium, omega 3 fatty acids and one or more pharmaceutically acceptable carriers.

Novel synergistic pharmaceutical composition for topical applications

A synergistic pharmaceutical composition for the preparation of topical formulations for use in prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers, diabetic foot ulcers and other skin diseases is provided. The composition may include one or more synergistically active ingredients and one or more inactive ingredients. The synergistically active ingredients may include Recombinant Human Epidermal Growth Factor (rh-EGF) (REGEN-D™ of Bharat Biotech International Limited) and/or Platelet Derived Growth Factor (rh-PDGF-BB), silver sulfadiazine (SSD) and chlorhexidine gluconate (CHG). One or more inactive ingredients may comprise carriers, preservatives, emulsifiers, skin emollients and soothers and one or more other constituents.

HAIR GROWTH STIMULANT

A composition of a mixture of vitamin and herbal supplements. Supplementation of the composition promotes hair growth and thickness by increasing the number of hairs and preventing hair loss. The concentration of the vitamin and herbal supplements in the composition is suitably about 0.01-100%. The composition may comprise a suitable carrier, solvent and/or emulgent. The composition may be, for example, an internally ingested tablet, a capsule, drops or a suspension. This formulation will enhance the hair thickness and provide elements for growing hair in humans and animals. 1. Promoting hair growth and preventing hair loss thereof administering a composition of mixed vitamin and herbal supplements wherein said concentration of a mixed vitamin and herbal supplements is about 0.1%.2. The composition of claim 1 , wherein said composition of vitamin and herbal supplements are a mixture of Biotin claim 1 , Calcium claim 1 , Chromium claim 1 , Copper claim 1 , DHA-docosahexaenoic acid claim 1 , EPA-eicosapentaenoic acid claim 1 , Fish oil claim 1 , Folic acid claim 1 , Ginkgo biloba claim 1 , Ginseng claim 1 , Iodine claim 1 , Iron claim 1 , Magnesium claim 1 , Manganese claim 1 , Molybdenum claim 1 , Niacin claim 1 , Omega-3 claim 1 , Pantothenic acid claim 1 , Riboflavin claim 1 , Saw palmetto claim 1 , Selenium claim 1 , Thiamin claim 1 , Vitamin A claim 1 , Vitamin B12 claim 1 , Vitamin B6 claim 1 , Vitamin C claim 1 , Vitamin D-cholecalciferol claim 1 , Vitamin E claim 1 , Vitamin K claim 1 , and Zinc.3. The composition of claim 2 , wherein said composition comprises a suitable carrier claim 2 , solvent and/or emulgent.4. The composition of claim 2 , wherein said composition is administered in the form of an oral dosage.5. The composition of claim 2 , wherein said oral dosage is in the form of an internally ingested tablet claim 2 , a capsule claim 2 , drops or a suspension.6. The composition of claim 1 , wherein said oral dosage promotes healthy micronutrient ...

COMPOSITIONS AND METHODS FOR TREATING PARTIAL AND FULL THICKNESS WOUNDS AND INJURIES

The present invention provides compositions and methods for treating deep partial thickness or full thickness wounds or injuries. The present invention also provides compositions and methods for promoting healing and regeneration of impaired or damaged tissue at a site of such partial thickness or full thickness wounds or injuries, as well as promoting vascularization and angiogenesis in regenerating and/or supportive tissue at such sites. 1. A method of treating , promoting healing at and/or promoting vascularization of a wound or injury site in a subject in need thereof , the method comprising:a) applying a composition comprising a biocompatible matrix and an effective amount of platelet-derived growth factor (PDGF) disposed therein to the site.2. The method according to claim 1 , wherein the wound or injury site comprises impairment or damage to at least one tissue selected from the group consisting of bone claim 1 , periosteum claim 1 , tendon claim 1 , muscle tissue claim 1 , fascia claim 1 , nerve tissue claim 1 , a visceral organ claim 1 , subcutaneous tissue claim 1 , integument claim 1 , and combinations thereof.3. The method according to claim 1 , wherein the wound or injury site is a deep partial or full thickness wound or injury site.4. The method of claim 1 , wherein the method further comprises debriding at least a portion of a site of impaired claim 1 , damaged claim 1 , or necrotic tissue prior to performing step (a).5. The method of claim 1 , wherein the method further comprises decorticating at least a portion of impaired or damaged bone at the site prior to performing step (a).6. The method of claim 1 , wherein at least one intramarrow bone penetration is performed at the site.7. The method according to claim 1 , wherein the injury is caused by at least one of the following: a blunt force trauma; a penetrating trauma; a gunshot wound; a microbial infection; a necrotizing infection; a bacterial infection; a fungal infection; hypothermia; frostbite; ...

COMPOSITION POSSESSING ANTIOXIDANT, IMMONOMODULATED, AND ANTITUMOROUS ACTION AND METHOD OF TREATING NEOPLASMS

A composition produces antioxidant, immunomodulated, and antitumorous effects. The composition includes tannic acid, potassium iodide, and ascorbic acid. The tannic acid, the potassium iodide; and the ascorbic acid preferably are in a weight ratio of 3:1:1. The potassium iodide is preferably in a mole ratio with the tannic acid of 1:2.5 to 3.5. The composition can be used in methods for treating skin neoplasms by dissolving the composition in a physiological solution and administering the solution intravenously. 1. A composition producing antioxidant , immunomodulated , and antitumorous effects , comprising:tannic acid;potassium iodide; andascorbic acid;said tannic acid, said potassium iodide; and said ascorbic acid being in a weight ratio of 3:1:1.2. A method for treating skin neoplasms claim 1 , which comprises administering the composition according to .3. The method according to claim 2 , which further comprises:dissolving said composition in a physiological solution;administering said solution intravenously dropwise once per day in a dose of 1.8-2.5 mg/kg of body mass for 15 to 20 days.4. A composition producing antioxidant claim 2 , immunomodulated and antitumorous effects claim 2 , comprising:potassium iodide; andtannic acid;said potassium iodide being in a mole ratio with said tannic acid of 1:2.5-3.5.5. The method according to claim 1 , which further comprises:dissolving said composition in a physiological solution;administering said solution intravenously.6. A method of treating neoplasts claim 1 , which comprises intravenously administering a composition including tannic acid and potassium iodide. This application is a continuation-in-part of prior application Ser. No. 12/492,874, filed Jun. 26, 2009.This application claims priority under 35 USC §119 of Ukrainian Patent Application No. 2008/08513, which is incorporated by reference.Not ApplicableNot ApplicableNot Applicable1. Field of the InventionThe invention relates to compositions and methods for ...

NUTRIENT COMPOSITIONS AND METHODS FOR ENHANCED EFFECTIVENESS OF THE IMMUNE SYSTEM

Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine. 127-. (canceled)28. A method of increasing a mammal's CD4+ cell count while undergoing therapy for treatment of a condition selected from the group consisting of immune-mediated diseases , cancer , heart disease , neurodegenerative disease , and infectious disease , comprising:administering to the mammal, during a treatment period, a nutrient composition and at least one drug effective for treatment of said condition; 1.43 mg to 11.42 mg alpha lipoic acid;', '3.57 mg to 28.58 mg acetyl L-carnitine; and', '4.28 mg to 34.28 mg N-acetyl-cysteine;, 'the nutrient composition comprising, in per kg body weight per daywhereby the mammal's CD4+ cell count is increased during the treatment period.29. The method of claim 28 , wherein the nutrient composition further comprises one or more vitamins or minerals selected from the group consisting of zinc claim 28 , selenium claim 28 , vitamin C claim 28 , bioflavinoid complex claim 28 , vitamin E claim 28 , beta-carotene claim 28 , vitamin A claim 28 , vitamin B1 claim 28 , vitamin B2 claim 28 , vitamin B6 claim 28 , niacinamide claim 28 , calcium panthothenate claim 28 , folic acid claim 28 , vitamin B12 claim 28 , copper claim 28 , manganese claim 28 , chromium claim 28 , and molybdenum;30. The method of claim 28 , wherein the alpha-lipoic acid claim 28 , acetyl L-carnitine claim 28 , and N-acetyl-cysteine are present in the nutrient composition in a ratio from 1:1:1 to 1:4:6.31. The method of claim 28 , wherein the treatment period is from about three to about twelve weeks.32. The method of claim 28 , wherein the treatment period is at least fifteen weeks.33. The method of claim 28 , ...

Methods for Reducing Cholesteron Using Bacillus Coagulans Spores, Systems and Compositions

The invention describes therapeutic compositions including a lactic acid-producing bacteria, such as isolated Bacillus coagulans, in combination with a cholesterol-reducing agent for use in reducing LDL cholesterol and serum triglycerides. Also described are therapeutic methods using the compositions and systems containing the therapeutic compositions.

IODINATED ACTIVATED CHARCOAL FOR TREATING SYMPTOMS OF DEPRESSION

The present invention relates to the use of iodinated activated charcoal, optionally in combination with a bromide salt, in treatment of one or more symptom(s) caused by depression, wherein said symptom(s) is/are selected from the group consisting depressive mood, emotional fatigue, mental fatigue which can be chronic, burnout, withdrawal from social situations, anxiety, concentration problems, unpleasant heart palpitations, irregular heart beats, a feeling of pressure in the chest, irritable bowel syndrome and sexual dysfunction. 127.-. (canceled)28. A method for treatment of one or more symptom(s) caused by depression in a mammal in need thereof , wherein said symptom(s) is/are selected from the group consisting of depressive mood , emotional fatigue , mental fatigue which can be chronic , burnout , withdrawal from social situations , anxiety , concentration problems , unpleasant heart palpitations , irregular heart beats , a feeling of pressure in the chest , irritable bowel syndrome and sexual dysfunction , the method comprising administering a pharmacologically effective amount of iodinated activated charcoal comprising elemental iodine to the intestine of said mammal.29. The method of claim 28 , wherein the iodinated activated charcoal is administered in combination with a pharmaceutically acceptable bromide salt.30. The method of claim 29 , wherein the bromide salt is sodium bromide claim 29 , potassium bromide claim 29 , magnesium bromide claim 29 , lithium bromide claim 29 , ammonium bromide and/or calcium bromide.31. The method of claim 29 , wherein the bromide salt is administered in an amount of 1-1000% w/w of the elemental iodine on the iodinated activated charcoal.32. The method of claim 28 , wherein the amount of elemental iodine administered is 1-20% w/w of the amount of the iodinated activated charcoal administered.33. The method of claim 28 , wherein the mammal is a human and wherein the human is administered a daily dose of elemental iodine from 1 ...

HYDROGEN IODIDE-CONTAINING HEALTH FOOD AND HYDROGEN IODIDE-CONTAINING DRUG, AND METHOD FOR PRODUCING SAME

To propose a health food or a drug, which comprises an iodine compound as a substitute for organic iodine and can exert a similar effect as organic iodine. To propose a method for producing a liquid to be used as a starting material for the aforesaid health food or drug. A health food and a drug each containing hydrogen iodide as the active ingredient. A method for producing a hydrogen iodide-containing solution, which comprises: an alkaline ion water preparation step for preparing alkaline ion water containing hydrogen peroxide; a sodium hydroxide production step for adding sodium to the alkaline ion water and thus producing sodium hydroxide; and a hydrogen iodide production step for, after the sodium hydroxide production step, adding iodine to the alkaline ion water and thus producing hydrogen iodide. 1. A health food , comprising:hydrogen iodide as an active ingredient.2. A liquid health food , comprising:hydrogen iodide as an active ingredient.3. The liquid health food according to claim 2 ,wherein acid level of the health food indicates alkaline property.4. A pharmaceutical product claim 2 , comprising:hydrogen iodide as an active ingredient.5. A liquid pharmaceutical product claim 2 , comprising:hydrogen iodide as an active ingredient.6. The liquid pharmaceutical product according to claim 5 ,wherein acid level of the pharmaceutical product indicates alkaline property.7. A method for producing hydrogen iodide-containing solution claim 5 , comprising:preparing alkali ion water containing hydrogen peroxide;producing sodium hydroxide by adding sodium to the alkali ion water; andproducing hydrogen iodide by adding iodine to the alkali ion water after producing the sodium hydroxide. The present invention relates to health foods for promotion of health and pharmaceutical products for prevention and treatment of diseases.Conventionally, iodine has been used as an ingredient for antiseptic or hemostatic. However, iodine is a highly responsive substance, and when ...

Compositions for improving mental performance

The present invention provides formulas for producing compositions for the structural/functional nutritional support for those who struggle with poor focus, concentration and/or memory. In addition, the present invention provides compositions comprising nutritional/botanical factors helpful to those who subjectively experience transient mental fatigue or poor cognitive function. The compositions of this invention consist primarily of the following ingredients B-complex vitamins, antioxidants, minerals, phosphatidyl serine (PS), choline, dimenthyl-aminoethanol (DMAE), docosahexaenoic acid (DHA), L-pyroglutamic acid, as well as herbal extracts from Bacopa monniera, Vinca minor , and Huperzia serrata . The present invention also relates to the administration of these compounds to alleviate mental fatigue or poor cognitive function.

Antibacterial agent for treating infectious diseases of bacterial origin

The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and radioprotective properties; in acceptable concentrations of components can be used as non-pharmaceutical agent (BAFS or parapharmaceutical); is presented in the pharmacological form suitable for parenteral, oral, external, or other application. INSC has the formula [{(Ln(MeI3)+)y[Me(Lm)I]+x}(Cl—)y+x+k] with M=30-300 kDa.

LOW SURFACTANT IODINE TOPICAL DISINFECTANT

Iodine-containing germicidal compositions are disclosed that remain physically stable for extended storage periods with little to no iodine complexing agent being present. The compositions employ a mixture of emollients, such as glycerin and ethoxylanolin, to create a composition that in certain embodiments presents a cloudy or emulsion-like appearance. 1. A ready-to-use germicidal composition comprising:from about 10 to about 50% by weight of a primary emollient selected from the group consisting of glycerin, propylene glycol, sorbitol, polyethylene glycol, and mixtures thereof;from about 0.05 to about 10% by weight of a water-soluble lanolin derivative; andfrom about 0.05 to about 1.5% by weight of iodine,said composition comprising less than 1% by weight of an iodine complexing agent,said composition being ready to apply to an animal's teat without further dilution.2. The germicidal composition according to claim 1 , wherein said composition further comprises a thickener.3. The germicidal composition according to claim 2 , wherein said thickener comprises up to 5% by weight of said composition and is selected from the group consisting of hydroxy ethylcellulose and carboxy methylcellulose claim 2 , sodium alginate claim 2 , xanthan gum claim 2 , gum arabic claim 2 , and mixtures thereof.4. The germicidal composition according to claim 1 , wherein said water-soluble lanolin derivative comprises an alkoxylated lanolin.5. The germicidal composition according to claim 4 , wherein said alkoxylated lanolin comprises ethoxylated lanolin.6. The germicidal composition according to claim 1 , wherein said primary emollient comprises glycerin.7. The germicidal composition according to claim 1 , wherein said composition comprises less than 1% by weight of a surfactant or polymer iodine complexing agent.8. The germicidal composition according to claim 1 , wherein said composition has a viscosity of between about 2 to about 5000 cP.9. The germicidal composition according to ...

Iodine Liquid Soap, Dispenser and Method

A iodine liquid soap dispenser having a reservoir containing an iodine solution. The dispenser has a head communicating with the reservoir capable of delivering the solution to the exterior of the reservoir in the form of foam. The solution comprises water, iodine and iodide, and contains iodine in a range of concentration between 0.35% and 0.05% by weight of the solution. The solution may also contain one or more of the following: an anionic surfactant, Hydrogen Iodide, glycerine, and sodium hydroxide.

Veterinary Compositions For Controlling Ecto- And Endoparasites In Bovines, Use Of These Compositions, Use Of IGR Substances Associated With Microminerals, Method For Controlling Ecto- And Endoparasites In Bovines And Kit

Veterinary compositions are described for controlling ecto- and endo-parasites in animals, such as bovine. The compositions contain an IGR compound(s) or a benzoyl substituted urea(s) along with a mineral mix and at least one carrier.

MEDICINAL PREPARATION "RENESSANS" HAVING AN ANTIBACTERIAL, ANTI-ULCEROUS AND IMMUNO-MODULATING ACTION

The invention relates to the field of medicine, particularly to medical preparations of anti-bacterial, anti-ulcer and immune simulating effects, which can be used in injection form. The medical preparation “RENESSANS” contains components in the following ratio (wt %): 2. The medical preparation of claim 1 , characterized in that the medical preparation is intended for intravenous claim 1 , intramuscular or oral administration to a patient in a pharmaceutically effective amount.3. The medical preparation of claim 1 , the use of the medical preparation being for treatment of viral and bacterial infections of mammals claim 1 , including humans.4. The medical preparation of claim 1 , the use of the medical preparation being for treatment of peptic ulcer disease of mammals claim 1 , including humans.5. The medical preparation of claim 1 , the use of the medical preparation being for increasing immunity of mammals claim 1 , including humans. This application claims the benefit of the priority filing date of PCT application no. PCT/KZ2011/000018 filed on Nov. 10, 2011 and published in WO2012/158002 on Nov. 22, 2012. The earliest priority filing date claimed is May 16, 2011.Not ApplicableNot ApplicableThe invention relates to the pharmaceutical industry, in particular, iodine-containing pharmaceuticals.Nowadays iodine medications occupy an important place among modern antiseptics. Many infections are caused by agents that are sensitive to iodine-containing medications which exhibit fungicidal, cellulicidal and antiprotozoal actions, and which act against some spores while not developing an acquired resistance to them.The problem of using iodine is that high concentrations are toxic, irritating the skin and mucous membranes. However, in combination with polysaccharides and polymers, iodine largely loses toxicity, and operates more slowly and continuously (during 5 hours), while maintaining anti-virus and anti-microbial properties (Nikulin V., V. Gerasimenko, 2008; E. ...

OPHTHALMIC COMPOSITION COMPRISING PVP-I

An ophthalmic composition includes Povidone-iodine (PVP-I) at a concentration of between 0.2%-1.0% (w/w). The ophthalmic composition has an aqueous phase and an oil phase, the oil phase constituting medium-chain triglycerides and the oil phase constituting less than 3% of the total weight of the composition. 113.-. (canceled)14. An ophthalmic composition comprising an aqueous phase , an oil phase , and Povidone-iodine (PVP-I) at a concentration of between 0.2%-1.0% (w/w) , said oil phase consisting of medium-chain triglycerides and said oil phase comprising less than 3% of a total weight of said composition.15. The ophthalmic composition according to claim 14 , wherein said PVP-I is at a concentration of between 0.4 and 0.8% w/w.16. The ophthalmic composition according to claim 14 , wherein said triglycerides are selected from one or more of caproic acid claim 14 , caprylic acid claim 14 , capric acid and lauric acid.17. The ophthalmic composition according to claim 14 , wherein said triglycerides are present in amounts of between 0.05 and 1% w/w.18. The ophthalmic composition according to claim 14 , further comprising a surfactant claim 14 , wherein said surfactant is in amounts of between 0.05 and 4% w/w and said surfactant is d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS).19. The ophthalmic composition according to claim 18 , further comprising an iodide in amounts of between 0.01 and 1.0% w/w claim 18 , wherein said iodide is potassium iodide or sodium iodide.20. The ophthalmic composition according to claim 14 , which is buffered claim 14 , with phosphate or citrate buffer claim 14 , in a pH range of between 4.5 and 6.5.21. The ophthalmic composition according to claim 14 , further comprising osmotizing agents selected from glycerol and sodium chloride and/or viscosizers.22. The ophthalmic composition according to claim 14 , comprising:PVP-I 0.4-0.8% w/w;medium chain triglycerides 0.1-0.9% w/w;TPGS 0.2-2.0% w/w;water;having a pH of between 4.5 and 6.5 ...

Novel ophthalmic composition and methods of use

Described are stable topical formulations useful in the treatment of viral infection, demodex infection and bacterial infection of the eye, and methods of using the compositions for treating viral infection, demodex infection and bacterial infection of the eye.

ANTIFUNGAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND NAILS

The invention concerns a composition and method for treating an ungual infection, the composition comprising an iodophor and dimethylsulfoxide (DMSO). 1. A composition for treating an ungual infection , the composition comprising:(a) an iodophor; and(b) dimethylsulfoxide (DMSO);wherein the composition is capable of penetrating the unguis to treat the infection.2. A composition for treating an ungual infection , the composition comprising:(a) elemental iodine; and(b) dimethylsulfoxide (DMSO);wherein the composition is capable of penetrating the unguis to treat the infection.3. The composition of claim 1 , wherein the iodophor is selected from the group consisting of povidone iodine (PVP-I) claim 1 , iodine tincture claim 1 , Lugol's solution claim 1 , potassium iodide claim 1 , and sodium iodide.4. The composition of claim 3 , where in the iodophor is PVP-I.5. The composition of claim 1 , wherein the composition is substantially anhydrous.6. The composition of claim 1 , wherein the composition is anhydrous.7. The composition of claim 3 , wherein PVP-I is present at about 0.01% to about 10% (w/w).8. The composition of claim 3 , wherein PVP-I is present in a range selected from the group consisting of about 0.05% to about 10% claim 3 , about 0.1% to about 5% claim 3 , about 0.2% to about 2.5% claim 3 , and about 0.5% to about 1% (w/w).9. The composition of claim 3 , wherein PVP-I is present in a range selected from the group consisting of about 0.1% claim 3 , about 0.2% claim 3 , about 0.3% claim 3 , about 0.4% claim 3 , about 0.5% claim 3 , about 1.0% claim 3 , about 1.25% claim 3 , about 1.5% claim 3 , about 2.0% claim 3 , about 2.5% claim 3 , and about 5% (w/w).10. The composition of claim 3 , wherein PVP-I is present at about 1% (w/w).11. The composition of claim 1 , further comprising at least one naturopathic substance.12Camellia SinensisCalendula OfficinalisGlycrrhiza GlabraCucumis Sativus. The composition of claim 1 , further comprising at least one substance ...

Phospholipid Ether Analogs for Imaging and Targeted Treatment of Pediatric Solid Tumors

It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphophocholine analogs are compounds having the formula: 2. The method of claim 1 , wherein the radioactive iodine isotope is selected from the group consisting of I claim 1 , I and I.3. The method of claim 1 , wherein n is 18 claim 1 , and the radioactive iodine isotope is I claim 1 , I or I (the compound is [I]-CLR1404 claim 1 , [I]-CLR1404 or [I]-CLR1404).4. The method of claim 1 , wherein the compound is administered by parenteral claim 1 , intranasal claim 1 , sublingual claim 1 , rectal claim 1 , or transdermal delivery.5. The method of claim 1 , wherein the malignant pediatric solid tumor that is treated is selected from the group consisting of neuroblastoma (NB) claim 1 , Ewings sarcoma (EWS) claim 1 , osteosarcoma (OS) claim 1 , retinoblastoma (RB) Wilms' tumor (WT) claim 1 , and pediatric brain tumors.7. The method of claim 6 , wherein the radioactive iodine isotope is selected from the group consisting of I claim 6 , I and I.8. The method of claim 7 , wherein n is 18 claim 7 , and the radioactive iodine isotope is I claim 7 , I or I (the compound is [I]-CLR1404 claim 7 , [I]-CLR1404 or [I]-CLR1404).9. The method of claim 6 , wherein the malignant pediatric solid tumor cells are selected from the group consisting of neuroblastoma (NB) cells claim 6 , Ewings sarcoma (EWS) cells claim 6 , osteosarcoma (OS) cells claim 6 , retinoblastoma (RB) cells claim 6 , Wilms' tumor (WT) cells claim 6 , and pediatric brain tumor cells.11. The method of claim 10 , wherein Ris a fluorophore claim 10 , and wherein the signals characteristic of the fluorophore comprise optical signals.12. The method of claim 11 , wherein the fluorophore is BODIPY or IR-775.13. The method of claim 11 , wherein the compound is CLR1501 or CLR1502.14. The method of claim 13 , wherein the radioactive iodine isotope is selected from the group consisting of I ...

MULTI-NUTRIENT SUPPLEMENT COMPOSITION AND USES THEREOF

Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease. 1. (canceled)2. A method of delaying or preventing the onset of a disease and/or condition associated with oxidative stress comprising administering to a human subject a therapeutically effective amount of a composition comprising:(i) vitamin A, vitamin B1 vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, calcium source, potassium source, magnesium source, phosphate source, iodine, copper source, chromium source, manganese source, molybdenum source, selenium source, zinc source, lycopene, one or more carotenoids, one or more flavonoids, biotin, inositol, choline, one or more amino acids,(ii) a probiotic composition comprising the powder of one or more dried fruits and pollen extract or Terminalia arjuna or an extract thereof,(iii) fish oil, and(iv) one or more pharmaceutically acceptable excipients;wherein the composition delays or prevents the onset of a disease and/or condition associated with oxidative stress.3. The method of claim 2 , wherein the composition comprises vitamin A (0.01-10 mg) claim 2 , vitamin B(1-50 mg) claim 2 , vitamin B(1-50 mg) claim 2 , vitamin B(1-100 mg) claim 2 , vitamin B(1-100 mg) claim 2 , vitamin B(0.5-50 mg) claim 2 , vitamin B(0.0001-2 mg) claim 2 , vitamin C (0.1-1000 mg) claim 2 , vitamin D (0.0001-1 mg) claim 2 , vitamin E (1-500 mg) claim 2 , vitamin K (0.001-5 mg) claim 2 , folic acid (0.0001-5 mg) claim 2 , calcium source (0.1-1000 mg) claim 2 , potassium source (0.1-1000 mg) claim 2 , magnesium source (0.1-1000 mg) claim 2 , phosphate source (1-500 mg) iodine source (0.0001-5 mg) claim 2 , copper source (0.0001-10 mg) claim 2 , chromium source (0.0001-10 rug) ...

Trace elements

A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.

NOVEL IODOPHOR COMPOSITION AND METHODS OF USE

Described are stable topical formulations useful in the treatment of viral wart infection, demodex infection and bacterial infection of the skin, and genitalia and the method of treating viral wart infection, demodex infection and bacterial infection of the skin, and genitalia with said compositions. 143-. (canceled)45. The composition of claim 44 , comprising 0.5% to 5% PVP-I.46. The composition of claim 44 , comprising 40% to 49% DMSO.47. The composition of claim 44 , comprising 1% to 4% gelling agent.48. The composition of claim 44 , comprising:0.1%-2% PVP-I;44% DMSO;1% to 3% hydroxyethylcellulose; andaqueous solvent.49. The composition of claim 44 , wherein the gelling agent is selected from the group consisting of a gum claim 44 , agar claim 44 , petrolatum claim 44 , and a cellulosic polymer.50. The composition of claim 44 , wherein the gelling agent is hydroxyethyl cellulose.52. The composition of claim 51 , comprising 0.15% to 0.5% PVP-I.53. The composition of claim 51 , comprising about 1% to about 3% gelling agent.55. The method of wherein said infection is caused by or associated with one or more infectious agents selected from the group consisting of bacteria claim 54 , demodex claim 54 , fungus or yeast claim 54 , and virus.56. The method of wherein the virus infectious agent is human papilloma virus (HPV).57. The method of wherein the infection is an infectious condition of the skin of the face or genitalia.58. The method of claim 54 , wherein the infection is an infectious condition of the eye or eyelid claim 54 , said method comprising applying to the eye or eyelid as needed to reduce or eliminate the infection claim 54 , an effective amount of a stable claim 54 , topical ophthalmic gel composition comprising0.1% to 5% povidone-iodine (PVP-I);30% to 99% dimethyl sulfoxide (DMSO);1% to 3% gelling agent.59. The method of wherein said infectious condition is selected from the group consisting of blepharitis claim 58 , conjunctivitis claim 58 , corneal ...

COMPOSITION FOR TRANSDERMAL DELIVERY AND METHODS THEREOF

Embodiments of the presently-disclosed subject matter include compositions that include iodine or salts thereof as well as methods administering the same to subjects in need thereof. In some embodiments the compositions comprise an aqueous solution, a surfactant, a cosurfactant, an oil, and iodine or salts thereof. The composition can be an emulsion. Methods for administration include topical administration, and in some embodiments the compositions can be administered transdermally by applying the composition directly to the skin of a subject. In some embodiments the compositions are topically administered with a spray applicator that dispenses a predetermined amount of the composition upon being actuated. 1. A composition , comprising:an aqueous solution;a surfactant;a cosurfactant;an oil; andiodine or salts thereof.2. The composition of claim 1 , wherein the iodine or salts thereof is selected from potassium iodide claim 1 , copper iodide claim 1 , zinc iodide claim 1 , sodium iodide claim 1 , and combinations thereof.3. The composition of claim 1 , wherein the surfactant is selected from anionic surfactants claim 1 , cationic surfactants claim 1 , nonionic surfactants claim 1 , zwitterionic surfactants claim 1 , and combinations thereof.4. The composition of claim 1 , wherein the surfactant includes sorbitan laurate (Span 20).5. The composition of claim 1 , wherein the cosurfactant includes an alcohol.6. The composition of claim 5 , wherein the cosurfactant includes ethanol.7. The composition of claim 1 , wherein the oil is selected from a volatile oil claim 1 , a non-volatile oil claim 1 , and combinations thereof.8. The composition of claim 1 , wherein the oil includes propylene glycol monocaprylate (type II).9. The composition of claim 1 , including sorbitan laurate (Span 20) claim 1 , an alcohol claim 1 , and propylene glycol monocaprylate (type II).10. The composition of claim 1 , comprising about 0.1 to about 50 wt % aqueous solution claim 1 , about 0.1 to ...

Multi-Stage Nasal Filter

Devices and methods of inhibiting the inhalation of particulates using a resiliently deformable filter packaged in a sealed envelope containing a liquid medium. The method includes opening the sealed package to thereby expose the filter to ambient air; removing the filter from the package; inserting the filter into a distal region of a nostril; and urging the filter from the distal region to a proximal region of the nostril while simultaneously swabbing the distal region with the liquid disinfectant. The filter includes: an initial stage characterized by a first pore size; an intermediate stage characterized by a second pore size; and a final stage characterized by a third pore size, wherein the third pore size is a smaller than the first and second pore sizes. 1. A method of impeding the inhalation of particulates using a resiliently deformable filter packaged in a sealed envelope containing a liquid medium , the method comprising:opening the sealed package to thereby expose the filter to ambient air;removing the filter from the package;inserting the filter into a distal region of a nostril; andurging the filter from the distal region to a proximal region of the nostril while simultaneously swabbing the distal region with liquid medium present on the perimeter of the filter.2. The method of wherein the filter is characterized by a mean pore size in the range of 0.5 to 50 micrometers (um).3. The method of wherein the particulates comprise allergens claim 1 , and further wherein the filter is characterized by a mean pore size in the range of 3 to 7 um.4. The method of wherein the liquid medium comprises an antiseptic.5. The method of wherein the liquid medium comprises a disinfectant.6. The method of wherein the particulates comprise microorganisms.7. The method of wherein the particulates comprise allergens.8. The method of wherein the filter comprises electrostatic material.9. The method of wherein the liquid medium comprises povidone iodine.10. The method of ...

COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING

The invention relates to a composition for enhancing wound healing and/or for reducing pain and inflammation, comprising a first active ingredient and a second active ingredient, wherein the first active ingredient comprises an antiseptic and the second active ingredient comprises an admixture of at least one vitamin, at least one mineral and at least one amino acid, and to use of the composition for enhancing wound healing. 140-. (canceled)41. A composition for enhancing wound healing and/or for reducing pain and inflammation , comprising a first active ingredient and a second active ingredient , wherein the first active ingredient comprises an antiseptic and the second active ingredient comprises an admixture of the carbohydrates dextrose , fructose and inulin , the amino acids glycine , arginine , glutamine and lysine , at least one vitamin , and at least one mineral.421. The composition of claim , wherein the second active ingredient comprises dextrose in an amount of 800 mg to 1200 mg , fructose in an amount of from 200 mg to 300 mg , and inulin in amount of 400 to 600 mg , per 3.5 grams of the second active ingredient.431. The composition of claim , wherein the second active ingredient comprises glutamine in an amount of 100 mg to 200 mg , lysine in an amount of 20 mg to 100 mg , arginine in an amount of 10 mg to 30 mg , per 3.5 grams of second active ingredient , and wherein the ratio of glycine to arginine is in the range of from 19:1 to 18:1 by weight.441. The composition of claim , wherein the antiseptic is a bis-biguanide compound.454. The composition of claim , wherein the bis-biguanide compound is chlorhexidine or a chlorhexidine salt.465. The composition of claim , wherein the chlorhexidine compound is chlorhexidine-digluconate.471. The composition of claim , wherein the first active ingredient is a 0.01% to 3% bis-biguanide compound.481. The composition of claim , wherein the antiseptic is iodine.491. The composition of claim , wherein the antiseptic ...

COMPOSITIONS AND METHODS FOR MANAGING DIGESTIVE DISORDERS AND A HEALTHY MICROBIOME

Disclosed is a prebiotic composition comprising a combination of 2′fucosyllactose (2′FL) and isomaltooligosaccharide (IMO). The 2′FL and IMO are present in the prebiotic composition in a weight ratio of from 1:1 to 1:10. The prebiotic composition is effective for use in methods of preventing and/or treating a gastrointestinal (GI) condition in an animal, such as irritable bowel syndrome (IBS), inflammatory bowel disease(s) (IBD), Crohn's disease, and ulcerative colitis (UC). A foodstuff or beverage, a medical food, a nutritional composition, and a kit presentation, each including the prebiotic composition, and each suitable for use in methods of reducing or suppressing inflammation in an animalian tract, are also disclosed. A method of using the prebiotic composition to prevent and/or treat a GI condition in an animal is further disclosed. The method comprises administering the prebiotic composition to the animal. 1. A prebiotic composition comprising a combination of 2′fucosyllactose (2′FL) and isomaltooligosaccharide (IMO) in a weight ratio of from 1:1 to 1:10.2. The prebiotic composition of claim 1 , wherein the combination comprises the 2′FL and IMO in a weight ratio of from 1:2 to 1:5 claim 1 , alternatively of 1:2.53. The prebiotic composition of claim 1 , wherein the prebiotic composition is (i) adapted to be consumed as a liquid; (ii) a dry powder; (iii) adapted to be mixed with a foodstuff; or (iv) any combination of (i) to (iii).4. The prebiotic composition of claim 1 , further comprising at least one additive comprising: (i) an amino acid; (ii) a peptide; (iii) a protein; (iv) a lipid; (v) a vitamin; (vi) a carbohydrate; (vii) a nucleic acid; (viii) a mineral; (ix) an anabolic nutrient; (x) an antioxidant; (xi) a probiotic bacterial strain; (xii) a lipotropic agent; or (xiii) any combination of (i) to (xii).5. The prebiotic composition of claim 4 , wherein the at least one additive comprises the (i) amino acid claim 4 , the (ii) peptide claim 4 , and/or ...

SPRAYABLE OXYGENATED SALINE COMPOSITION AND METHOD FOR TREATING NASAL CONGESTION, ALLERGY, DRYNESS, EYE IRRITATION, THROAT IRRITATION, WOUNDS, AND SKIN AS APPLIED TO HUMAN TISSUES

An oxygenated saline composition is provided comprising stabilized oxygen, sodium chloride (aqueous saline solution), and optionally one or more homeopathic components. The stabilized oxygen can include quad-atomic oxygen. Also provided is a method for treating, reducing or preventing nasal and/or sinus congestion, allergy, dryness, throat irritation, skin irritation, wounds, or eye irritation comprising administering to an individual in need thereof an effective amount of an oxygenated saline composition comprising stabilized oxygen, aqueous saline solution, and optionally one or more homeopathic components, wherein the composition is administered by intranasal spraying, throat spray, skin spray, sublingually, or by eye drops.

Phospholipid Ether Analogs for Imaging and Targeted Treatment of Pediatric Solid Tumors

It is disclosed herein that that certain alkylphosphocholine analogs are preferentially taken up by malignant pediatric tumor cells. The alkylphophocholine analogs are compounds having the formula: or salts thereof, wherein n is an integer from 12 to 24; and R 2 is —N + (CH 3 ) 3 . The compounds can be used to treat pediatric solid tumors or to detect pediatric solid tumors. In therapeutic treatment, R 1 includes a radioactive iodine isotope that locally delivers therapeutic dosages of radiation to the malignant pediatric tumor cells that preferentially take up the compound. In detection/imaging applications, R 1 includes a detection moiety, such as a fluorophore or a radioactive iodine isotope.

COMPOSITIONS OF NUTRITION SUPPLEMENTATION FOR NUTRITIONAL DEFICIENCIES AND METHOD OF USE THEREOF

A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement. 127.-. (canceled)28. A method for treating conditions associated with abnormally slow energy metabolism or high energy requirement , comprising:administering to a subject in need of such treatment a daily nutritional supplement having total calories of about 700-980 kcal, wherein about 10-20% of the total calories are derived from protein, about 25-40% of the total calories are derived from fat, and about 45-65% of the total calories are derived from carbohydrate.29. The method of claim 28 , wherein the conditions associated with abnormally slow energy metabolism include malnutrition claim 28 , anorexia claim 28 , cancers claim 28 , AIDS and aging.30. The method of claim 28 , wherein the conditions associated with high energy requirement include sickle cell anemia claim 28 , pregnancy claim 28 , lactation claim 28 , growth claim 28 , exercise claim 28 , infectious diseases and recovery from surgical and other injuries.31. The method of claim 30 , wherein the condition associated with high energy requirement is sickle cell anemia.32. The method of claim 28 , wherein the nutritional supplement is administered orally in the form of a snack.33. The method of claim 32 , wherein the nutritional supplement is administered orally as the last snack before sleeping.34. The method of claim 32 , wherein the nutritional supplement is administered as snacks after each meal.35. A nutritional supplement to normal diet for treating conditions associated with abnormally slow energy metabolism or high energy requirement claim 32 , comprising:protein in an amount that provides about 10-20 ...

HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY

The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof. 1. A method for treating or preventing an injury or disease in a subject , comprising providing to said subject a composition comprising a halogen compound and a pharmaceutically acceptable carrier , diluent , or excipient.2. (canceled)3. The method of claim 1 , wherein said halogen compound comprises iodine.4. (canceled)5. The method of claim 3 , wherein said halogen compound is an iodide.6. The method of claim 5 , wherein said iodide is sodium iodide claim 5 , potassium iodide claim 5 , hydrogen iodide claim 5 , calcium iodide claim 5 , or silver iodide.710.-. (canceled)11. The method of claim 1 , wherein the halogen is present in the halogen compound in a reduced form.12. The method of claim 1 , wherein said composition is provided to the subject parenterally or orally.13. The method of claim 12 , wherein said composition is provided to the subject intravenously or by infusion.14. The method of claim 13 , wherein said composition is formulated for intravenous administration claim 13 , administration by infusion claim 13 , or oral administration and wherein the composition comprises a stable reduced form of the halogen compound.15. The method of claim 1 , wherein said composition is provided to the subject in an amount sufficient to increase the blood concentration of the halogen at least 100% claim 1 , at least 200% claim 1 , at least 300% claim 1 , at least 400% claim 1 , or at least 500% for at least some time.16Salmonella. The method of claim 1 , wherein said disease or injury is selected from any of the ...

MICRO- AND NANO-QUANTITY SLEEP ENHANCING NUTRIENT COMPOSITION AND METHOD OF ENHANCING CENTRAL NERVOUS SYSTEM PROTEIN CLEARANCE USING SAME

The present invention relates to a dietary supplement, composition, nutraceutical, and/or system for inducing or treating biological responses or conditions (namely sleep or sleep disorders) which utilize ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, stimulants, and/or similar ingredients in a highly bio-active delivery system which bypasses first pass metabolism. In particular, the present invention relates to a nutraceutical composition/formulation which substantially bypasses first pass metabolism and such as, but not limited to, activation of the glymphatic system to facilitate clearance of neuronal metabolites from the CSF and interstitial fluids in the brain. 1. A nutraceutical composition comprising micro- or nano-quantities of the following ingredients in an oral preparation suitable for oral administration to a person in need thereof , the ingredients comprising , in combination at least one mineral or salts thereof selected from the group consisting of magnesium , sodium , potassium , calcium , chromium , copper , iron and zinc , at least one vitamin selected from the group consisting of A , B1 , B2 , B3 , B6 , B12 , folic acid , C , D3 , E and H , at least one antioxidant , and at least one amino acid.2. The nutraceutical composition of claim 1 , wherein the at least one mineral further comprises a chloride salt claim 1 , a carbonate claim 1 , an ascorbate claim 1 , a nitrite claim 1 , a picolinate claim 1 , a polynicotinate claim 1 , a benzoate or an iodide.3. The nutraceutical composition of claim 1 , wherein the at least one mineral further comprises claim 1 , in combination claim 1 , magnesium chloride claim 1 , sodium ascorbate claim 1 , sodium nitrite claim 1 , potassium carbonate claim 1 , calcium ascorbate claim 1 , potassium benzoate claim 1 , chromium picolinate claim 1 , chromium polynicotinate claim 1 , potassium sorbate claim 1 , potassium iodide claim 1 , calcium carbonate claim 1 , iron claim 1 , copper and zinc.4 ...

NOVEL OPHTHALMIC COMPOSITION AND METHODS OF USE

Described are stable topical formulations useful in the treatment of viral infection, demodex infection and bacterial infection of the eye, and methods of using the compositions for treating viral infection, demodex infection and bacterial infection of the eye. 2. The composition of claim 1 , comprising 0.15% to 1.0% PVP-I.3. The composition of claim 1 , comprising 0.25% to 0.5% PVP-I.4. The composition of claim 1 , comprising about 0.25% PVP-I.5. The composition of claim 1 , comprising 30% to 70% DMSO.6. The composition of claim 1 , comprising 40% to 49% DMSO.7. The composition of claim 1 , comprising 44% DMSO.8. The composition of claim 1 , comprising 2% to 3% gelling agent.29. The composition of comprising 3% gelling agent.11. The composition of claim 10 , wherein the co-solvent is water or aqueous isotonic solution.12. A stable gel composition of claim 1 , wherein claim 1 , the composition is a topical ophthalmic preparation wherein each ingredient is ophthalmically acceptable claim 1 , andsaid ophthalmic gel composition retains at least 85% of titratable iodine in povidone-iodine starting material for at least 72 hours.13. The stable gel composition of wherein the composition retains at least 85% of titratable iodine in povidone-iodine starting material for at least one month.14. The stable gel composition of wherein the composition retains at least 85% of titratable iodine in povidone-iodine starting material for up to 12 months.15. A method of treating an infectious condition of the eye or eyelid claim 12 , said method comprising the step of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'applying an effective amount of a stable, topical ophthalmic gel composition of to a site of the infection as needed to reduce or eliminate the infection.'}16. The method of wherein said infectious condition is selected from the group consisting of blepharitis claim 15 , conjunctivitis claim 15 , corneal ulcer claim 15 , bacterial keratitis claim 15 , viral keratitis ...

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESS

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods. 1. A stable pharmaceutical composition for use in corneal collagen cross-linking , comprising (a) iodide , (b) riboflavin , and (c) a pharmaceutically-acceptable excipient appropriate for ocular administration , wherein the pharmaceutical composition maintains a basic pH that permits iodide ion to catalytically break hydrogen peroxide into water and oxygen.2. The pharmaceutical composition of claim 1 , wherein the basic pH is between 7 and 8.4.3. The pharmaceutical composition of claim 2 , further comprising a reducing agent.4. The pharmaceutical composition of claim 3 , wherein the reducing agent is thiosulfate claim 3 , vitamin C claim 3 , or sodium bisulfate.5. The pharmaceutical composition of claim 1 , wherein the pharmaceutically-acceptable excipient is an artificial tear solution.6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a solution adapted for introduction into the eye and diffusion into the cornea for promoting photochemical corneal cross-linking and reducing oxidative stress.7. The method of claim 1 , wherein the pharmaceutical composition comprises between about 0.001% to about 10.0% iodide by weight.8. The method of claim 7 , wherein the pharmaceutical composition comprises between about 0.015% to about 5% iodide by weight.9. The method of claim 1 , wherein the ...

COMPOSITION FOR WOUND HEALING

The composition for wound healing facilitates healing of damaged tissues, promotes tissue and cell growth, protects cells and tissues, and reduces scar tissue. The composition includes hydrolyzed collagen, whey, and magnesium stearate. The composition for wound healing demonstrates improved flow, increasing the ease of manufacturing and application to a wound site. The hydrolyzed collagen may include bovine sourced hydrolyzed collagen and marine sourced hydrolyzed collagen. The composition may also include an additive, such as a therapeutic agent, an antimicrobial, a vitamin, or a preservative. 1. A composition for wound healing , comprising:about 30% to about 90% by weight hydrolyzed collagen;about 0.5% to about 60% by weight whey; andmagnesium stearate.2. The composition for wound healing of claim 1 , further comprising:about 30% to about 90% by weight bovine sourced hydrolyzed collagen;about 20% to about 50% by weight marine sourced hydrolyzed collagen;about 0.5% to about 60% by weight whey; andmagnesium stearate.3. The composition for wound healing of claim 2 , wherein the whey is hydrolyzed whey.4. The composition for wound healing of claim 2 , wherein the marine sourced hydrolyzed collagen is sourced from salmon.6. The composition for wound healing of claim 1 , further comprising a therapeutic agent.7. The composition for wound healing of claim 6 , wherein the therapeutic agent is selected from the group consisting of an antibiotic claim 6 , glutamine claim 6 , a glycosaminoglycan claim 6 , zinc claim 6 , an alginate claim 6 , copper chlorophillan claim 6 , fibronectin claim 6 , silver claim 6 , oxidized regenerated cellulose claim 6 , cellulose claim 6 , and honey.8. The composition for wound healing of claim 7 , wherein the glycosaminoglycan is selected from the group consisting of chondroitin sulfate claim 7 , keratin sulfate claim 7 , dermatic sulfate claim 7 , hyaluronic acid claim 7 , heparin claim 7 , and heparin sulfate.9. The composition for wound ...

NUTRITIONAL COMPOSITIONS

In some aspects, the disclosure relates to compositions useful for the dietary management of inborn errors of metabolism (e.g., PKU, MSUD, HCU, IVA, and MMA/PA). In some embodiments, the disclosure provides a composition comprising a protein source, a fat source, a carbohydrate source, at least one vitamin, and at least one mineral, wherein the protein source comprises at least six free amino acids. In some aspects the disclosure relates to compositions that support bone health. 1. A composition comprising: Vitamin D , calcium , phosphorus , zinc , magnesium , and Vitamin K , wherein the Vitamin D is between about 500 IU and about 770 IU of the total weight of the composition , calcium is between about 36% and about 56% of the total weight of the composition , phosphorus is between about 31% and about 48% of the total weight of the composition , zinc is between about 0.25% and about 0.40% of the total weight of the composition , magnesium is between about 8% and about 13% of the total weight of the composition , and Vitamin K is between about 1.2% and about 3.5% of the total weight of the composition.2. A composition comprising Vitamin D , calcium , phosphorus , zinc , magnesium , and Vitamin K , wherein in about 1.5 g to about 4.0 g of composition , Vitamin D is between about 500 IU and 770 IU , calcium is between about 500 mg and about 840 mg , phosphorus is between about 475 mg and about 720 mg , zinc is between about 4 mg and about 6 mg , magnesium is between about 125 mg and about 195 mg , and Vitamin K is between about 20 μg and about 50 μg.34-. (canceled)5. The composition of claim 1 , further comprising inulin.6. (canceled)7. The composition of claim 5 , wherein from about 0 g to about 2.5 g inulin is present in 3.5 g of the composition.89-. (canceled)10. A composition comprising a composition of and a protein source claim 1 , wherein Vitamin D is between about 500 IU per 20 g Protein Equivalent (PE) and 770 IU per 20 g PE claim 1 , calcium is between about ...

ANTIMICROBIAL COMPOSITIONS AND METHODS

Disclosed are compositions and methods for antimicrobial use. The compositions contain a small antimicrobial agent and a permeabilizing agent. The antimicrobial compositions can be antifungal or antibacterial compositions.

COMPOSITIONS FOR MANAGEMENT OF DISORDERS OF THE GASTROINTESTINAL TRACT

Effective and economical compositions and methods are disclosed for the treatment, and prevention of diseases and disorders associated with inflammation and/or damage to the gastrointestinal tract, including environmental enteric dysfunction. Compositions are provided comprising a synergistic combination of colostrum, immune egg, and optionally one or more additional active agents. 133-. (canceled)34. A method of treating or preventing a disease or disorder associated with inflammation or damage of the gastrointestinal tract in a subject in need thereof , the method comprising administering a non-neonate human effective amount of a composition comprising:a) an immune egg antibody product comprising at least one specific avian antibody, or antigen binding fragment thereof, that specifically binds to an antigenic region of a pathogenic component selected from a pathogenic organism, a pathogen-related toxin, a pathogen-related adhesion element, or combinations thereof; andb) a bovine colostrum.35. The method of claim 34 , wherein the method further comprises co-administering an effective amount of additional active agent.36. The method of wherein the composition further comprises an additional active agent.37. The method of claim 34 , wherein the disease or disorder is selected from the group consisting of environmental enteric disorder (EED) claim 34 , tropical sprue claim 34 , severe acute malnutrition claim 34 , inflammatory bowel disease claim 34 , irritable bowel syndrome claim 34 , non-steroidal antiinflammatory drug (NSAID) gastrointestinal disorder claim 34 , chemotherapy-induced mucositis claim 34 , radiation-induced mucositis claim 34 , pseudomembranous colitis claim 34 , gastritis claim 34 , peptic ulcers claim 34 , and necrotizing entercolitis.38. The method of claim 37 , wherein the inflammatory bowel disease is ulcerative colitis claim 37 , indeterminate colitis claim 37 , or Crohn's disease.39. The method claim 34 , wherein the subject is a non-neonate ...

Method for Increasing and Sustaining Free Radical Levels in Tissue of Interest

A method of creating and sustaining an elevated level of free radicals in a volume of targeted tissue that utilizes targeted nanostructures ( 16 ) that include a metallic component ( 26 ) that acts to amplify the effects of a free radical-producing stimulus; a magnetic component; and a binding component ( 24 ) that acts to bind to cellular components present in the targeted tissue. To practice the method, the targeted nanostructures are introduced into the targeted tissue and a free radical-producing stimulus, which may be in the form of a particle beam ( 20 ) is provided at the targeted tissue volume.

Treatment of macrophage-related disorders

The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.

Composition and method for treation oligoovulation, oligomenorrhea and amenorhea

A kit for treating Oligoovulation and/or Oligomenorrhea and/or Amenorrhea comprising a menstruation inducing composition comprising effective amounts of Vitamin A, Vitamin C, Vitamin D, Vitamin E, Vitamin B-1, Vitamin B-2, Vitamin B-3, Vitamin B-5, Vitamin B-6, Vitamin B-7, Vitamin B-9, Vitamin B-12, Iron, Iodine, Magnesium, Zinc, Selenium, Copper, Manganese, Chromium, Molybdenum, Boron, and Choline; and an ovulation regulating composition comprising effective amounts of calcium citrate, and magnesium citrate/aspartate. 1. A kit for treating a condition selected from the group consisting of Oligoovulation or Oligomenorrhea , or Amenorrhea and combinations thereof comprising: 'an effective amount of each of the following: Vitamin A, Vitamin C, Vitamin D, Vitamin E, Vitamin B-1, Vitamin B-2, Vitamin B-3, Vitamin B-5, Vitamin B-6, Vitamin B-7, Vitamin B-9, Vitamin B-12, Calcium, Iron, Iodine, Magnesium, Zinc, Selenium, Copper, Manganese, Chromium, Molybdenum, Boron and Choline; and', 'a menstruation inducing composition comprising'}an ovulation regulating composition comprising an effective amount of each of calcium citrate, and magnesium citrate/aspartate.2. The kit according to wherein the menstruation inducing composition comprises:approximate amount per serving of each of 4500 IU Vitamin A, 120 mg Vitamin C, 400 IU Vitamin D, 30 IU Vitamin E, 1.40 mg Vitamin B-1, 1.60 mg Vitamin B-2, 18.00 mg Vitamin B-3, 7.00 mg Vitamin B-5, 10.00 mg Vitamin B-6, 35.00 mcg Vitamin B-7, 1000.00 mcg Vitamin B-9, 8.00 mcg Vitamin B-12, 600.00 mg Calcium, 18.00 mg Iron, 290.00 mcg Iodine, 200.00 mg Magnesium, 15.00 mg Zinc, 70.00 mcg Selenium, 1.30 mg Copper, 2.60 mg Manganese, 45.00 mcg Chromium, 50.00 mg Molybdenum, 150.00 mcg Boron, and 550.00 mcg Choline.3. The kit according to wherein the ovulation regulating composition comprises:approximate amount per serving of each of 100.00 mg Calcium Citrate, and 50.00 mg Magnesium Citrate/Aspartate.4. The kit according to wherein the ...

Formulations that Provide Support During Vaccinations and Adaptive Immune System Response

The present invention provides formulations that support an individuals body during routine vaccination and adaptive immune response. The individuals who can benefit front these formulations are infants, children and adults. The formulations comprise ingredients that can be administered prior to, concurrent with or subsequent to the vaccination. The formulations of the present invention preferably act by targeting enzymatic reactions an individual's various metabolic pathways, maintaining balance between oxidative stress and methylation, maintaining balance between Th1 and Th2 responses, or a combination thereof during vaccination and adaptive immune response. 1. A formulation , comprising:thiamine (Vitamin B1), a derivative thereof or an analog thereof; riboflavin (Vitamin B2a derivative thereof or an analog thereof, niacin (Vitamin B3), a derivative thereof or an analog thereof; pantothenic acid (Vitamin B5), a derivative thereof or an analog thereof; Vitamin B6, a derivative thereof or an analog thereof; folate (Vitamin B9), a derivative thereof or an analog thereof; cobalamin (Vitamin B12), a derivative thereof or an analog thereof; Vitamin A, a derivative thereof or an analog thereof; Vitamin D, a derivative thereof or an ,analog thereof; Vitamin F. derivative thereof or an analog thereof; Vitamin C, a derivative thereof or an analog thereof; Vitamin K, a derivative thereof or an analog thereof; calcium, a derivative thereof or an analog thereof; iodine, a derivative thereof or an analog thereof; magnesium, a derivative thereof or an analog thereof; zinc, a derivative thereof or an analog thereof; selenium, a derivative thereof or an analog thereof; manganese, a derivative thereof or an analog thereof; chromium, a derivative thereof or an analog thereof; molybdenum, a derivative thereof or an analog thereof; trimethylglycine (betaine), a derivative thereof or analog thereof; choline, a derivative thereof or an analog thereof; acetyl-L-carnitine, a derivative ...

STABILIZED LIQUID ENZYME SUPPLEMENT AND USES THEREOF

An enzyme containing composition is provided comprising a stabilized liquid enzyme supplement encapsulated in phospholipid structures. The enzyme supplements may be administered to humans so that the enzymes are rapidly absorbed into the blood and tissues in order to improve metabolism, immune competence, sleep quality, and aid digestion, in addition to general health, well-being, and overall quality of life. 1. A method for delivering an enzyme supplement , comprising the steps of:{'claim-text': ['a solvent,', 'phosphatidylcholine of at least 70% purity, and', 'an ionic mineral composition; and'], '#text': '(a) providing a formulation comprising at least one enzyme encapsulated in a multilamellar clustoidal phospholipid vehicle, the multilamellar clustoidal phospholipid vehicle comprising:'}(b) orally administering the formulation to a human subject.2. The method of claim 1 , wherein the at least one enzyme is selected from the group consisting of a protease claim 1 , a lipase claim 1 , a carbohydrase claim 1 , and an amylase.4. The method of claim 3 , wherein total cholesterol levels do not increase in the human subject 90 days after administering the formulation to the human subject.5. The method of claim 3 , wherein serum low density lipoprotein (LDL) levels do not increase in the human subject 90 days after administering the formulation to the human subject.6. The method of claim 3 , wherein serum high density lipoprotein (HDL) levels do not decrease in the human subject 90 days after administering the formulation to the human subject.7. The method of claim 3 , wherein sleep quality as measured by Pittsburgh Sleep Quality Assessment (PSQI) score is increased in the human subject 90 days after administering the formulation to the human subject in comparison with placebo.8. The method of claim 3 , wherein quality of life (QOL) as measured by World Health Organization Quality of Life (WHOQOL-BREF) score is increased in the human subject 90 days after administering ...

NUTRITIONAL COMPOSITION

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. The present invention is comprised of specific combinations of selected forms of unique sets of certain vitamins, minerals, protein, carbohydrates and phytochemicals. 1. An orally administrable nutritional composition comprising:selenium yeast;0.5 mg to 1.5 g fish oil, the fish oil having a combined EPA/DHA content of between 10% to 90% and an EPA/DHA ratio of between 1:5 and 5:1; and500 iu to 10,000 iu beta carotene;a milk protein;a rice protein; andinositol,wherein components of the nutritional composition are provided in amounts effective to both reduce cachectic symptoms and suppress neoplastic growth in the cancer patient when provided in combination.2. The nutritional composition of claim 1 , wherein the selenium yeast is in an amount from 10 μg to 250 μg.3. The nutritional composition of claim 1 , wherein the selenium yeast is in an amount from 25 μg to 1500 μg.4Saccharomyces cerevisiae, Saccharomyces exiguous, Saccharomyces pastorianus, Saccharomyces boulardii, Saccharomyces bayanus, Saccharomyces eubayanus, Saccharomyces florentinusSaccharomyces fragilis.. The nutritional composition of claim 1 , wherein the selenium yeast is one or more of the group consisting of: claim 1 , and5. The nutritional composition of claim 1 , wherein the fish oil has an EPA/DHA content of between 30% to 70%.6. The nutritional composition of claim 1 , wherein the fish oil has an EPA/DHA content of between 40% to 60%.7. The nutritional composition of claim 1 , wherein the fish oil has an EPA/DHA ratio of about 2:1.8. The nutritional composition of claim 1 , wherein the fish oil has an EPA/DHA ratio of about 3:2.9. The ...

METHODS OF USING OPHTHALMIC COMPOSITIONS COMPRISING POVIDONE-IODINE

A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient. 1. An ophthalmic composition suitable for topical administration to an eye , effective for treatment and/or prophylaxis of a microorganism infection or a disorder of at least one tissue of the eye , comprisinga) povidone-iodine in a concentration between 0.01% and 10%, andb) An anti-inflammatory, a steroid, or a combination thereof.2. The ophthalmic composition of wherein said povidone-iodine is between 0.1% and 2.5% by weight.3. The ophthalmic composition of wherein said povidone-iodine is between 0.5% and 2% by weight.4. The ophthalmic composition of wherein a total weight of said povidone-iodine claim 1 , said anti-inflammatory claim 1 , and said steroid is between 0.1% and 4.5% in said solution.5. The ophthalmic composition of wherein said anti-inflammatory agent is selected from the group consisting of ketotifen fumarate claim 1 , diclofenac sodium claim 1 , flurbiprofen sodium claim 1 , ketorlac tromethamine claim 1 , suprofen claim 1 , ceiccoxib claim 1 , naproxen claim 1 , rofecoxib claim 1 , and a combination thereof.6. The ophthalmic composition of wherein said steroid is at a concentration of between 0.01 and 10%.7. The ophthalmic composition of wherein said steroid is at a concentration of between 0.05 and 2%.8. The ophthalmic composition of wherein said steroid is selected from the group consisting of dexamethasone claim 1 , dexamethasone ...

A NUTRITIONAL COMPOSITION COMPRISING A COMBINATION OF HUMAN MILK OLIGOSACCHARIDES TO IMPROVE THE GASTROINTESTINAL BARRIER

The present invention relates to nutritional compositions comprising 2′-Fucosyllactose (2′FL), Di-fucosyllactose (Di-FL), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), 3′-Sialyllactose (3′SL) and 6′-Sialyllactose (6′SL) for use in improving gastrointestinal barrier. In particular, the present invention relates to improving the gastrointestinal barrier in an infant, a young child or children aged above 3 years to 8 years.

Dietetic multi-component system

An improved multi-component system containing a main component and at least one additional component that is physically separated from the main component, and a use of the system as a food supplement and a pharmaceutical product.

NUTRACEUTICAL FORMULATION FOR POLYCYSTIC OVARY SYNDROME

Nutraceutical food supplement for treatment of young women in post-puberty age suffering from polycystic ovary syndrome with symptoms like irregular menstruation cycles, insulin resistant diabetes, infertility, hair loss, acne and weight gain is provided. Formulations having myo-inositol and its D-chiro isomer along with plant proteins, a carbohydrate (inulin) and other plant fibres; along with well-defined proportions of vitamins (A, B; Band C); several minerals like Ca, Cr, Fe, K, Mg, Mn, Na and Zn and essential amino acids like L-Glutamine, L-Lysine, and L-Taurine are provided. 1. A nutraceutical composition comprising a protein and an inositol.2. The nutraceutical composition of claim 1 , further comprising folic acid.3. The nutraceutical composition of claim 1 , further comprising a folate.4. The nutraceutical composition of claim 1 , further comprising a component selected from the group consisting of a vitamin claim 1 , a vitamin like substance claim 1 , a mineral claim 1 , a fiber claim 1 , an essential amino acid claim 1 , and combinations thereof.5. The nutraceutical composition of claim 1 , wherein the protein is selected from the group consisting of a protein of plant origin claim 1 , a protein of animal origin and combinations thereof.6. The nutraceutical composition of claim 1 , wherein the protein of plant origin is selected from the group consisting of a pea protein claim 1 , a rice protein and combinations thereof.7. The nutraceutical composition of claim 1 , wherein the inositol is selected from the group consisting of myoinositol claim 1 , d-chiro inositol and combinations thereof.8. The nutraceutical composition of claim 4 , wherein the vitamin selected from the group consisting of vitamin A claim 4 , vitamin B1 claim 4 , vitamin B2 claim 4 , vitamin B3 claim 4 , vitamin B4 claim 4 , vitamin B5 claim 4 , vitamin B6 claim 4 , vitamin C claim 4 , vitamin D and combinations thereof.9. The nutraceutical composition of claim 4 , wherein the vitamin ...

CLOSTRIDIUM DIFFICILE SPORICIDAL COMPOSITIONS

Disclosed are sporicidal compositions, and methods of use thereof. The sporicidal compositions contain water, an organic solvent, and a spore-germinating agent containing an iodide source, a citrate source or both. The compositions have sporicidal activity against, e.g., spores. The sporicidal compositions can be used alone, or can form part of a disinfecting composition or an antiseptic composition. 1. A sporicidal composition , comprising:water;{'sub': s', 's, 'an amount qof organic solvent, wherein qis about 5% to about 60% w/w; and'}{'sub': g1', 'g1, 'an amount qof spore-germinating agent, wherein qis about 0.05% to about 5% w/w;'} the organic solvent comprises a glycol, glycerine, a glycol ether, a polyethylene glycol or dimethyl isosorbide; and', [{'sub': 'i1', 'an amount qof iodide source, or'}, {'sub': 'c1', 'an amount qof citrate source, or'}, 'a combination thereof;', [{'sub': g1', 'i1', 'c1, 'q≧q+q; and'}, {'sub': i1', 'c1, 'at least one of qand qis at least about 0.05% w/w.'}], 'wherein], 'the spore-germinating agent comprises], 'wherein2. The sporicidal composition of claim 1 , [{'sub': 'i1', 'an amount qof iodide source, or'}, {'sub': 'c1', 'an amount qof citrate source, or'}, 'a combination thereof;', [{'sub': g1', '1i', 'c1, 'q≧q+q; and'}, {'sub': i1', 'c1, 'at least one of qand qis at least about 0.05% w/w.'}], 'wherein], 'the spore-germinating agent consists essentially of, 'wherein3. The sporicidal composition of claim 2 , {'sub': g1', 'i1', 'c1, 'q=q+q.'}, 'wherein4. The sporicidal composition of claim 1 , [{'sub': 'g1', 'qis about 0.10% to about 2.3% w/w; and'}, {'sub': i1', 'c1, 'at least one of qand qis at least about 0.10% w/w.'}], 'wherein529-. (canceled)30. A sporicidal composition claim 1 , comprising:water;{'sub': s', 's, 'an amount qorganic solvent, wherein qis about 5% to about 60% w/w; and'}{'sub': g2', 'g2, 'an amount qspore-germinating agent, wherein qis about 0.03% to about 3.8% w/w;'} the organic solvent comprises a glycol, ...

TREATMENT OF MICROBIAL INFECTIONS

The present application relates to an anti-microbial system for use in the treatment of microbial infections or control of microbial contamination, which avoids the use of antibiotics. Such infections include mastitis, tuberculosis, cystic fibrosis and the contamination that may result from biofilm formation on medical devices. 1. A microbiocidal composition comprising a reactive oxygen species or components capable of producing a reactive oxygen species , the composition being capable of delivering to an infection site the reactive oxygen species to a level of at least 0.4 millimoles per litre , over a 24 hour period.2. The composition as claimed in capable of delivering the reactive oxygen species to a level of at least 0.5 millimoles per litre claim 1 , over a 24 hour period.3. The composition as claimed in wherein the reactive oxygen species is produced by the reaction of a peroxidase claim 1 , a substrate for the peroxidase and hydrogen peroxide.4. The composition as claimed in where the reactive oxygen species is selected from the group comprising hypothiocyanate (hypothiocyanite claim 1 , SCNO) claim 1 , hypoiodate (IO) and hypochlorite (CLO).5. The composition as claimed in wherein the peroxidase enzyme is selected from the group comprising a lactoperoxidase claim 3 , a chloroperoxidase claim 3 , a bromoperoxidase and an iodooxidase.6. The composition as claimed in comprising a lactoperoxidase enzyme and further comprising iodide or thiocyanate ions.7. The composition as claimed in comprising a chloroperoxidase enzyme and further comprising chloride ions.8. The composition as claimed in where the source of hydrogen peroxide is a solution of the hydrogen peroxide.9. The composition as claimed in where the hydrogen peroxide is released by a hydrogen peroxide releasing compound selected from the group comprising percarbonates claim 3 , citric acid and perhydrates claim 3 , or by enzymatic methods.10. The composition as claimed in where the hydrogen peroxide is ...

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION

A method for improving a nutritional status in a prenatal, pregnant or breastfeeding patient. The method includes providing a pharmaceutical composition in a single oral dosage form for administration to a prenatal, pregnant or breastfeeding patient. The pharmaceutical composition consists of vitamin D, iodine, vitamin B1, vitamin B6, vitamin B12, vitamin B2, vitamin B9, vitamin B3, vitamin E, vitamin A, vitamin C, iron, zinc, copper, magnesium, omega-3 fatty acids and one or more pharmaceutically acceptable carriers. The method further includes providing a daily dosage regimen for administering the single oral dosage form to the patient to improve a nutritional status in the patient. 132-. (canceled)33. A method for improving a nutritional status in a prenatal , pregnant or breastfeeding patient , the method comprising:administering to the prenatal, pregnant or breastfeeding patient, a single oral dosage form of a pharmaceutical composition consisting of:vitamin D in an amount of about 400 I.U. to about 1600 I.U.,vitamin B1 in an amount of about 0.8 mg to about 2.4 mg,vitamin B6vitamin B12,vitamin B2 in an amount of about 0.9 mg to about 2.7 mg,vitamin B9 in an amount of about 0.5 mg to about 1.5 mg,vitamin B3 in an amount of about 7.5 mg to about 22.5 mg,vitamin E in an amount of about 10 I.U. to about 30 I.U.,vitamin A,vitamin C,iron,zinc in an amount of about 12.5 mg to about 37.5 mg,copper in an amount of about 1.0 mg to about 3.0 mg,optionally iodine in an amount of about 75 μg to about 225 μg,optionally magnesium in an amount of about 10 mg to about 30 mg,optionally omega-3 fatty acids in an amount of about 100 mg to about 300 mg andone or more pharmaceutically acceptable carriers;wherein the single oral dosage form is administered in a daily dosage regimen to the prenatal, pregnant or breastfeeding patient and improves the nutritional status in the prenatal, pregnant or breastfeeding patient.34. The method of claim 33 , wherein the single oral dosage form ...

NOVEL OPHTHALMIC COMPOSITION AND METHODS OF USE

Described are stable topical formulations useful in the treatment of viral infection, demodex infection, fungal infection and bacterial infection of the eye, and methods of using the compositions for treating viral infection, demodex infection, fungal infection and bacterial infection of the eye. 1. A stable gel composition comprising0.15% to 1.5% povidone-iodine (PVP-I);30% to 97% dimethyl sulfoxide (DMSO);0.25% to less than 2.0% gelling agent; andwater or isotonic co-solventwherein, the composition has a pH less than 4.5, and is free of additional anti-inflammatory drug.2. The stable gel composition of claim 1 , comprising 0.15% to 1.25% PVP-I.3. The stable gel composition of claim 1 , comprising 0.25% to 1.0% PVP-I4. The stable gel composition of claim 1 , comprising about 0.25% PVP-I.5. The stable gel composition of claim 1 , comprising about 0.50% PVP-I.6. The stable gel composition of claim 1 , comprising about 0.75% PVP-I.7. The stable gel composition of claim 1 , comprising 300/% to 70% DMSO.8. The stable gel composition of claim 1 , comprising 40% to 49% DMSO.9. The stable gel composition of claim 1 , comprising 44% DMSO.10. The stable gel composition of claim 1 , comprising about 0.25% gelling agent.11. The stable gel composition of claim 1 , comprising about 0.50% gelling agent.12. The stable gel composition of claim 1 , comprising about 1.0% gelling agent.13. The stable gel composition of claim 1 , comprising about 1.25% gelling agent.14. The stable gel composition of claim 1 , comprising about 1.50% gelling agent.15. The stable gel composition of comprising 1.75% gelling agent.16. The stable gel composition of wherein the gelling agent is a cellulosic polymer.17. The stable gel composition of wherein the gelling agent is hydroxyethyl cellulose (HEC).18. The stable gel composition of claim 1 , comprising:0.25% PVP-I;44% DMSO;greater than 0.25% and less than 2.0% gelling agent; anda co-solvent, andwherein said composition is steroid-free and NSAID-free.19 ...

ANHYDROUS HYDROGEL COMPOSITION

The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API's), coagulants, fragrances, flavors, and other actives and excipients. 1. An active agent delivery system , comprising i. sodium carboxymethyl cellulose (NaCMC) in an amount of from 5% (w/w) to 30% (w/w), said sodium carboxymethyl cellulose including minimal residual water, and', 'ii. anhydrous glycerine in an amount of from 70% (w/w) to 95% (w/w);, 'a. a solid or semi-solid gel composition, the solid or semi-solid gel composition comprisingb. an active agent; andc. a rate controlling membrane.2. The active agent delivery system of claim 1 , wherein the active agent delivery system is a patch claim 1 , capsule claim 1 , lozenge or chew.3. The active agent delivery system of claim 1 , wherein the amount of active agent is from 0.1% (w/w) to 30% (w/w).4. The active agent delivery system of claim 1 , wherein the solid or semi-solid gel composition includes an interior claim 1 , a reservoir is within the interior and the reservoir includes the active agent.5. The active agent delivery system of claim 1 , wherein said active agent is cannabidiol (CBD).6. The active agent delivery system of claim 1 , wherein said active agent is selected from cannabidiol (CBD) oil and tetrahydrocannabinol (THC) oil.7. The active agent delivery system of claim 1 , wherein said active agent is a moisture sensitive active agent and said moisture sensitive active agent comprises pharmaceutical agents including biologicals claim 1 , enzymes claim 1 , proteins and fragments thereof claim 1 , Adderall claim 1 , alprazolam claim 1 , gemifloxacin claim 1 , hydromorphone and zolmitriptan.8. The active agent delivery system of claim 1 , wherein said active agent is a pharmaceutical agent selected from analgesics claim 1 , decongestants claim 1 , bronchodilators claim 1 , antiasthmatic agents claim 1 ...

LIPID BARRIER REPAIR

The present disclosure is in the field of ointments which can be useful for the treatment of diseases or conditions associated with lipid barrier damage of the skin. The ointment comprises a semifluorinated alkane and a solid thickening agent, e.g., a wax, a triglyceride, cetyl alcohol, cetyl palmitate, or tetradecanol. 1. A composition in form of an ointment , comprising:a) a semifluorinated alkane;b) a solid thickening agent; andc) optionally an excipient.2. The composition according to claim 1 , wherein the composition further comprises an active ingredient.3. The composition of claim 1 , wherein the semifluorinated alkane is selected from 1-perfluorohexyl-octane (F6H8) claim 1 , 1-perfluorbutyl-pentane (F4H5) claim 1 , 1-perfluorobutyl-decane (F4H10) claim 1 , 1-perfluorobutyl-octane (F4H8) claim 1 , 1-perfluorohexyl-decane (F6H10) claim 1 , and combinations thereof.4. The composition of claim 1 , wherein the composition comprises 80-97 wt. % of the semifluorinated alkane and 3-11 wt % of the thickening agent claim 1 , based on the total weight of the composition.5. The composition of claim 1 , wherein the solid thickening agent is selected from plant waxes claim 1 , animal waxes claim 1 , petroleum derived waxes claim 1 , triglycerides claim 1 , cetyl alcohol claim 1 , cetyl palmitate claim 1 , tetradecanol claim 1 , and combinations thereof.6. The composition of claim 1 , wherein the thickening agent is a wax selected from the group consisting of bees wax claim 1 , lanolin (wool wax) claim 1 , carnauba wax claim 1 , candelilla wax claim 1 , castor wax claim 1 , rice bran wax (rice wax) claim 1 , spermaceti wax claim 1 , jojoba oil claim 1 , bran wax claim 1 , montan wax claim 1 , kapok wax claim 1 , bay berry wax claim 1 , shellac wax claim 1 , sugar cane wax claim 1 , paraffin wax claim 1 , and ceresin wax.7. The composition of claim 1 , wherein the excipient is selected from one or more co-solvents or oily materials.8. The composition of claim 1 , wherein ...

JELLY-LIKE MEDICINAL COMPOSITION OF POTASSIUM IODIDE

A jelly-like potassium iodide pharmaceutical composition exhibits excellent storage stability and excellent dissolution properties, and can be taken easily. The jelly-like potassium iodide pharmaceutical composition includes potassium iodide as an active ingredient, a gelling agent, and a dispersion medium. 1. A jelly-like pharmaceutical composition comprising potassium iodide as an active ingredient , a gelling agent , and a dispersion medium.2. The jelly-like pharmaceutical composition as defined in claim 1 , wherein the gelling agent is a carrageenan.3. The jelly-like pharmaceutical composition as defined in claim 1 , wherein the gelling agent is a combination of a carrageenan and carob bean gum.4. The jelly-like pharmaceutical composition as defined in claim 1 , further comprising a stabilizer claim 1 , wherein the stabilizer comprises any one from the group consisting of polyacrylic acid claim 1 , partially neutralized polyacrylic acid claim 1 , and a polyacrylic acid salt.5. The jelly-like pharmaceutical composition as defined in claim 1 , wherein the dispersion medium is a mixture that comprises glycerol and water.6. The jelly-like pharmaceutical composition as defined in claim 1 , further comprising at least one from the group consisting of a sweetener claim 1 , a buffer claim 1 , a preservative claim 1 , and a flavor. This application is a continuation of International Patent Application No. PCT/JP2015/053536, having an international filing date of Feb. 9, 2015, which designated the United States, the entirety of which is incorporated herein by reference. Japanese Patent Application No. 2014-163146 filed on Aug. 8, 2014 is also incorporated herein by reference in its entirety.The present invention relates to an iodine preparation (formulation). In particular, the invention relates to a jelly-like pharmaceutical composition.A potassium iodide pill and a potassium iodide powder (bulk powder) have been provided as iodine preparations.These iodine preparations ...

Nutraceutical composition and method of use thereof

A nutraceutical composition comprising water having an alkaline pH and a plurality of members of the group consisting of orange extract, vanilla extract, apple honey, agave syrup, apple cider vinegar, olive oil, coconut oil, liquid multivitamin, aloe vera juice, flax seed oil, hemp oil, and elephant garlic, wherein each of the plurality of members is present in an amount effective to ameliorate the effects of inflammation and raise energy levels when administered to a mammal.

System and Method For Packaging And Dispensing Disposable Garments

A system for distributing garments at a point-of-use. The system includes a dispenser and a plurality of substantially planar sheets each comprising an individual garment disposed within and configured to be dispensed from the dispenser. Each garment includes a torso; first and second sleeves extending from the torso; a pocket disposed on a front portion of the torso; and a through-hole disposed in the pocket and configured to receive a wire therethrough. 1. A recyclable perspiration garment configured to be worn on a user's body , comprising:a torso including a front portion and a back portion, each extending from a collar region to a waist band region;first and second sleeves extending from the torso;a pocket disposed on the front portion, the pocket having an open top and comprising an external pocket panel disposed parallel to and covering an internal pocket panel of the front portion, the external pocket panel forming a left edge seam, a right edge seam, and a bottom seam with the internal pocket panel;a through-hole disposed in the pocket and configured to receive a wire therethrough; andat least one perforation line configured to facilitate the manual tearing and removal of at least a portion of the garment from the user's body.2. The garment of claim 1 , wherein the perforation line is disposed in a pectoral region of the front portion.3. The garment of claim 1 , wherein the first and second sleeves are connected to the torso along respective sleeve perforation lines.3. The garment of claim 1 , wherein the through-hole is disposed in at least one of the internal pocket panel and the external pocket panel.4. The garment of claim 1 , further comprising a wire restraint connected to the front portion between the collar region and the pocket.5. The garment of claim 1 , further comprising: a second through-hole disposed in an upper region of one of the sleeves and configured to receive a wire therethrough.6. The garment of claim 1 , further comprising:a trouser ...

Enhanced Rodeferin Broad Spectrum

This process manufactures a finished medicine that can be used against broad spectrum, Anti-Viral, Anti-Bacterial, Anti-Fungal, and Anti-parasitic disease conditions that attack the human body but not limited to other medical conditions and or other types of treatments use for animals other than humans. 1. A medicine for treating disease , comprising:(a) a colloid;(b) a lipid bilayer material; and(c) methylthioninium chloride;(d) where the lipid bilayer material wraps around the colloid.2. The medicine for treating disease presented in claim 1 ,(a) wherein the colloid further comprises: colloid particles;(b) where the colloid particles are selected from one or more of the group consisting of Silver, Gold, Silica, Copper, Zinc, Iodine, Titanium, Platinum, Palladium, Iridium, Rhodium, Osmium, Iron, and Manganese.3. The medicine for treating disease presented in claim 2 ,(a) where the colloid particles range between 10 to 100 nm in size.4. The medicine for treating disease presented in claim 3 ,(a) where the colloid particles in the colloid are 20 to 300 ppm.5. The medicine for treating disease presented in claim 3 ,(a) where the colloid ranges from 5% to 95% by volume in the medicine.6. The medicine for treating disease presented in claim 5 ,(a) where the methylthioninium chloride ranges from 0.00125% to 1.9% by weight in the medicine.7. A medicine for treating disease claim 5 , comprising: (i) colloid particles;', '(ii) where the colloid particles consist of Silver, Gold, and Silica;, '(a) a colloid, the colloid comprising(b) a lipid bilayer material; and(c) methylthioninium chloride;(d) where the lipid bilayer material wraps around the colloid.8. The medicine for treating disease presented in claim 7 ,(a) where the colloid particles range between 10 to 100 nm in size.9. The medicine for treating disease presented in claim 8 ,(a) where the colloid particles in the colloid are 20 to 300 ppm.10. The medicine for treating disease presented in claim 8 ,(a) where the ...

ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR PRODUCTION

This invention relates to a method for preparing compositions for preventing or treating microbial infections, compositions suitable for use in such treatments and methods for treatment or prevention of infections. One such composition finds particular use in treating mastitis in ruminants. The composition is administered into the udder of an animal as a highly effective treatment for mastitis, or as a prophylactic therapy, by means of an intra-mammary infusion. The milk produced by the animal, during treatment using the composition and method of the invention, is free of residues, such as antibiotics, antimicrobial agents or antimicrobial proteins, which could affect its suitability for drinking or in the production of milk products, such as cheese or yoghurt. The compositions and methods are also useful in treating and preventing lung infections; and infections in burns and wounds; and other infections caused by biofilms. The compositions may also be used on medical devices to prevent infection. 1. A pharmaceutical composition comprising iodide (I−) and a source of hydrogen peroxide , together with a pharmaceutically effective carrier or diluent.2. The pharmaceutical composition according to claim 1 , where the concentration of hydrogen peroxide is less than 1% based on weight/volume or weight/weight.3. The pharmaceutical composition according to claim 1 , which does not include a peroxidase enzyme.4. The pharmaceutical composition according to comprising a 0.2:1 to 3:1 ratio by weight of iodide to hydrogen peroxide.5. The pharmaceutical composition according to comprising a 0.38:1 to 1.52:1 ratio by weight of iodide to hydrogen peroxide.6. The pharmaceutical composition according to claim 1 , containing 5-5 claim 1 ,000 mg iodide claim 1 , prepared at a ratio of between 0.2:1 and 3:1 by weight of iodide to hydrogen peroxide.7. The pharmaceutical composition according to claim 1 , containing 5-5 claim 1 ,000 mg iodide claim 1 , prepared at a preferable ratio of ...

PREVENTION OF INFECTION BY HIGHLY PATHOGENIC VIRUSES USING TOPICAL APPLICATION OF POVIDONE-IODINE ON MUCOUS MEMBRANES

This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine. 1. A method of reducing the risk , incidence or severity of systemic illness in a human subject caused by highly pathogenic viruses , the method comprising application to the nasal passages of the human subject an effective amount of a pharmaceutical preparation comprising povidone-iodine (PVP-I) at a concentration of greater than 0.10% w/v and less than about 1.25% w/v and where the preparation is applied prior to , during and/or immediately after exposure or possible exposure of the subject to the virus or an infected person wherein the highly pathogenic viruses is Ebola Virus (EBOV).2. The method as claimed in wherein the PVP-I preparation is applied up to 12 times daily into the nasal passages of a human subject claim 1 , commencing prior to claim 1 , during or after exposure to the filovirus and thereafter for a period approximately equivalent to the expected incubation period of the virus.3. The method as claimed in wherein the human subject is a healthcare worker who is claim 1 , or is likely to be claim 1 , exposed to the filovirus or filovirus infected patients.4. The method as claimed in claim 3 , wherein the PVP-I preparation is applied by the healthcare worker prior to exposure.5. The method as claimed in claim 1 , wherein the PVP-I concentration in the pharmaceutical preparation applied to the nasal passages is about 0.1% to about 1.0% w/v.6. The method as claimed in claim 5 , wherein the PVP-I concentration in the pharmaceutical preparation applied to the nasal passages is about 0.2% to about 0.5% w/v.7. The method as claimed in wherein the pharmaceutical preparation is an aqueous based intranasal preparation where water makes up from about 80% w/v to about 96% w/v of the total preparation.8. The method as claimed in wherein the ...

SYNBIOTIC COMPOSITIONS

A synbiotic preparation may include at least one probiotic strain and at least one amino acid or derivative thereof selected from glutamine, glutamic acid or salts thereof, conjugated glutamine, or oligopeptides of 2-10 amino acid units in length, wherein the amino acid units may be natural amino acids, and at least one amino acid unit being a glutamine or glutamic acid unit. 1. A preparation , comprising:{'i': ['Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens', 'Bacillus pumilus; and'], '#text': 'a probiotic strain comprising and/or'}an amino acid comprising glutamine, a salt of glutamine, glutamic acid, a salt of glutamic acid, conjugated glutamine, and/or an oligopeptide of 2-10 natural amino acid units in length, the oligopeptide comprising a glutamine or glutamic acid unit.2Bacillus subtilisBacillus subtilisBacillus licheniformisBacillus amyloliquefaciensBacillus subtilisBacillus pumilus. The preparation of claim 1 , wherein the probiotic strain is DSM 32315 claim 1 , DSM 32540 claim 1 , DSM 32314 claim 1 , CECT 5940 claim 1 , DSM 32592 claim 1 , and/or DSM 32539.3. The preparation of claim 1 , wherein the oligopeptide is present an further comprises an alanine or glycine unit.4. The preparation of claim 1 , wherein the oligopeptide is present and is a dipeptide claim 1 , andwherein the dipeptide comprises glycine-glutamine, glycine-glutamic acid, alanine-glutamine, and/or alanine-glutamic acid, the dipeptide being optionally acetylated.5. The preparation of claim 1 , wherein a total amount of probiotic strain and amino acid or oligopeptide is at least 40 wt. % of total preparation weight.6. The preparation of claim 1 , wherein the preparation comprises an enteric coating comprising a methyl acrylate-methacrylic acid copolymer claim 1 , cellulose acetate phthalate claim 1 , cellulose acetate succinate claim 1 , hydroxypropyl methyl cellulose phthalate claim 1 , hydroxypropyl methyl cellulose acetate succinate claim 1 , polyvinyl acetate ...

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESS

Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about % to about %, or more specifically between about % to about %, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods. 1. A method of treating a disease , disorder or condition characterized by unwanted or excessive oxidative stress in an individual in need thereof , comprising administering to the individual a pharmaceutical composition comprising between about 0.001% to about 10.0% sodium iodine or catalase by weight.27.-. (canceled)8. The method of claim 1 , wherein the disease claim 1 , disorder or condition is Glaucoma; Dry Eyes; Degenerative Retinal Damage (ARMD); Cataractogenesis; Retinopathy of Prematurity (ROP); Ocular Uveitis; Presbyopia; or Cataracts.9. A method for photochemical crosslinking comprising administering a pharmaceutical composition to the eye comprising (1) riboflavin claim 1 , and (2) an iodide ion.10. The method of claim 9 , wherein the pharmaceutical composition comprises between about 0.001% to about 10.0% sodium iodide by weight.11. The method of claim 9 , wherein the pharmaceutical composition comprises between about 0.015% to about 5% sodium iodide by weight.12. The method of claim 10 , wherein the pharmaceutical composition comprises about 0.015% sodium iodide by weight and about 0.5% riboflavin by weight.13. The method of claim 9 , wherein the composition has a basic pH.14. The method of claim 13 , wherein the basic pH is between 7 and 8.4.15. The method of claim 9 , wherein the pharmaceutical composition further comprises a ...

COMPOSITION AND METHOD FOR TREATING OTITIS

The invention concerns a composition and method for treating an otic infection, including otitis externa or otitis media, the composition comprising povidone iodine and dimethylsulfoxide (DMSO) and, optionally, a gelling agent. 1. An otic composition comprising 0.1%-10% w/w povidone-iodine and 30%-99% w/w DMSO and at least one optically acceptable excipient.2. The composition of claim 1 , wherein the composition comprises a gelling agent.3. The composition of claim 2 , wherein the gelling agent is selected from hydroxyethyl cellulose claim 2 , hydroxymethyl cellulose claim 2 , and hydroxypropyl methylcellulse.4. The composition of claim 1 , wherein the composition comprises PEG.5. The composition of claim 1 , wherein the composition comprises petrolatum.6. The composition of claim 1 , wherein the composition is steroid-free.7. A method for preventing or treating an otic infection or infestation claim 1 , said method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'applying or administering a composition of .'}8. The method of claim 6 , wherein the otic infection or infestation is ototis externa.9. The method of claim 6 , wherein the otic infection is otitis media.10. The method of claim 6 , wherein the otic infection is a viral infection.11. The method of claim 6 , wherein the otic infection or infestation is a bacterial infection.12. The method of claim 6 , wherein the otic infection or infestation is a fungal infection.13. The method of claim 6 , wherein the otic infection or infestation is amoebal infection or infestation.14. The method of claim 6 , wherein the composition of is steroid-free. This application is a continuation-in-part of pending U.S. patent application Ser. No. 15/213,289, filed Jul. 18, 2016, which is a continuation of U.S. patent application Ser. No. 14/116,360, filed as a 371 application from PCT/US2012/036942 filed May 8, 2012, and issued Aug. 9, 2016 as U.S. Pat. No. 9,408,867, each claiming the benefit of U.S. Provisional ...

Topical Supplement Composition and Method of Use

A topical supplement composition. The topical supplement composition includes one or more vitamins, minerals, or other nutrients, in combination with one or more suitable transdermal carriers. The topical supplement composition delivers vitamins, minerals or other nutrients via transdermal application from an individual's skin to the individual's bloodstream. 1) A topical multi-vitamin composition , comprising:Vitamin A;Vitamin B1;Vitamin B2;Vitamin B3;Vitamin B6;Vitamin B7;Vitamin B9;Vitamin B12;Vitamin C;Vitamin D;Vitamin E;Vitamin K2;Zinc;Calcium;Magnesium;Iron;Copper;Selenium;Iodine;Trimethylglycine;Grape Seed Oil;Rosehip Oil;Coconut Oil;Hemp Seed Oil;Aloe Vera Oil;Orange Peel Essential Oil;Cetearyl Alcohol;Coco-glucoside; andWater.2) The topical multi-vitamin composition of claim 1 , wherein Vitamin A is in the form of Retinol.3) The topical multi-vitamin composition of claim claim 1 , wherein Vitamin B6 is in the form of Pyridoxal-5′-phosphate.4) The topical multi-vitamin composition of claim 1 , wherein Zinc is in the form of Zinc Orotate.5) The topical multi-vitamin composition of claim claim 1 , wherein Calcium is in the form of Calcium Orotate.6) The topical multi-vitamin composition of claim 1 , wherein Magnesium is in the form of Magnesium Orotate.7) The topical multi-vitamin composition of claim claim 1 , wherein:an amount of Vitamin A is in the range of 400 micrograms to 3,000 micrograms;an amount of Vitamin B3 is in the range of 2 milligrams to 35 milligrams;an amount of Vitamin B6 is in the range of 0.1 milligrams to 100 milligrams;an amount of Vitamin B9 is in the range of 65 micrograms to 1,000 micrograms;an amount of Vitamin C is in the range of 15 milligrams to 2,000 milligrams;an amount of Vitamin E is in the range of 4 milligrams to 1,000 milligrams;an amount of Zinc is in the range of 2 milligrams to 40 milligrams;an amount of Calcium is in the range of 200 milligrams to 2,500 milligrams;an amount of Iron is in the range of 0.2 milligrams to ...

Dissolvable dietary supplement strip and methods for using the same

A strip, which is both edible and dissolvable, is provided comprising a film and a dosage of at least 2% of the reference daily intake (RDI) of at least one dietary supplement for malnutrition or to prevent/treat alcohol induced hangovers. A method for treating malnutrition and/or preventing and treating alcohol-induced hangovers using a dissolvable orally administered strip.

Antimicrobial substrates and methods for processing the same

Substrates having antimicrobial films or coatings adhered to a surface of the substrate and methods for replenishing the antimicrobial activity of films or coatings adhered to substrate surfaces are disclosed. The antimicrobial films and coatings comprise a strongly basic anion-exchange resin and an anion bound to the strongly basic anion-exchange resin, the anion being free of transition metals. The methods involve exposing a film or coating to an anion having antimicrobial activity, the anion being free of transition metals, and the film or coating comprising a strongly basic anion-exchange resin, thereby obtaining an antimicrobial film or coating comprising the anion bound to the strongly basic anion-exchange resin.

Automated Method and System for Introducing Molecular Iodine into Drinking Water

A system for delivering molecular iodine or other substance into a pet's drinking water on a daily basis without exceeding the safe amount allowed for the pet. The system delivers a particular amount of molecular iodine into the pet water supply to achieve maximum benefit of Ito reduce or eliminate bad pet breath and minimize total iodine in the pet diet so that 20-40 μg/mL/Kg/day iodine is consumed for optimum thyroid health. The preferred method is to use a solution created by dissolving iodine crystals in absolute ethanol. The iodine will only be in solution as Ifor a short time as it undergoes out gassing and hydrolysis at neutral pH. The present invention removes the iodine from the drinking water after the pet drinks. Therefore, during the day, pets will get no additional iodine—only fresh water. Each enrolled pet is electronically recognized by the system. 1. A method of injecting molecular iodine into a pet's drinking water comprising:automatically identifying a particular pet approaching a drinking bowl producing a pet identification;injecting a predetermined amount of molecular iodine into said drinking bowl for that particular pet, said predetermined amount determined by said pet identification;removing iodine from said drinking bowl when said pet leaves.2. The method of wherein said identifying is done with an RFID tag and RF ID reader.3. The method of further comprising also injecting a vitamin claim 1 , nutrient or drug into said drinking bowl.4. The method of wherein a particular pet is given iodine only on a predetermined schedule.5. An apparatus for injecting a particular substance into pet drinking water comprising:a pet-access drinking container;a filter cartridge;a circulation pump, wherein said circulation pump is adapted to pass water from said drinking container through said filter cartridge;a substance dispenser adapted to dispense a chemical solution into said drinking container;a pet identification module;a processor programmed use said pet ...

Composition for use in reducing scab formation and promoting healing

The present invention relates to a composition comprising at least one mono-glyceride chosen from glyceryl monocaprylate, glyceryl monolaurate and glyceryl monomyristate, and hydrophilic solvent, having a liquid crystalline lamellar structure at a temperature of above about 37° C., a solid crystalline lamellar structure below about 30° C. and a transformation of said solid and liquid crystalline lamellar structures at from about 30° C. to about 37° C., for use in treatment of cuts and wounds, said composition providing a moisturizing effect of said injury or wound, for reducing scab formation and promote healing in connection with injuries or wounds.

LIQUID CONCENTRATED FORMULA

The invention pertains to a liquid complete nutritional composition suitable for feeding cachectic patients, having an energy density of at least 1.45 kcal/ml. The composition comprises a protein fraction in an amount of 7.8-12 g per 100 ml, a carbohydrate fraction, and a lipid fraction. At least 70 wt. % of the protein fraction can be obtained by demineralising milk, e.g. by ultrafiltration. The carbohydrate fraction (17-27 g per 100 ml) can comprise 0-35 wt. % of sucrose, 15-45 wt. % of other non-reducing mono-, di- and/or trisaccharides, especially trehalose, 5-50 wt. % of other mono- and disaccharides and 5-40 wt. % of tri- and higher saccharides. The product is suitably packaged in small volumes (10-150 ml). 2. The liquid composition according to claim 1 , in which the demineralising is performed by ultrafiltration.3. The liquid composition according to claim 1 , in which the carbohydrate fraction comprises 15-45 wt. % of a non-reducing monosaccharide claim 1 , a non-reducing disaccharide and/or a non-reducing trisaccharide claim 1 , wherein the non-reducing disaccharide is not sucrose.4. The composition according to claim 3 , in which the non-reducing disaccharide is trehalose.5. The liquid composition according to claim 1 , in which the protein fraction comprises at least 1.0 wt. % of cysteine residues.6. The liquid composition according to claim 1 , further comprising 0.5-6 g fibre per 100 ml.7. (canceled)8. The liquid composition according to claim 6 , in which the protein fraction is in an amount of 8.7-12 g per 100 ml.9. The liquid composition according to claim 1 , in which the protein fraction comprises at least 8.6 wt. % of lysine residues claim 1 , at least 2.5 wt. % of methionine residues and at least 0.5 wt. % of cysteine residues.1012.-. (canceled)13. The liquid composition according to claim 1 , in which the lipid fraction is in an amount of 5.0-7.0 g per 100 ml.14. The liquid composition according to having a viscosity below 50 mPa·s at a shear ...

LEVOTHYROXINE LIQUID FORMULATIONS

The present invention is directed to a pharmaceutical product which includes a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes a cyclodextrin, water, and an amine, and has a pH above the buffering range of the amine. The liquid formulation of the invention is stable and ready-to-use. 1. A pharmaceutical product comprising an aqueous formulation for parenteral administration , the formulation comprising levothyroxine sodium at a concentration of from about 5 mcg/mL to about 100 mcg/mL and sulfobutylether β-cyclodextrin , wherein the formulation comprises an amine capable of stabilizing the levothyroxine in the formulation and has a pH above the buffering range of the amine , wherein , following storage for one week at 55° C. , the formulation contains not more than 2.0% liothyronine (T3) and not more than about 5% total impurities.2. The pharmaceutical product of claim 1 , wherein the formulation contains not more than 2.0% liothyronine (T3).3. The pharmaceutical product of claim 1 , wherein the total impurities are determined after storage for two months at 40° C.4. The pharmaceutical product of claim 1 , wherein the formulation retains at least about 95% of the initial concentration of levothyroxine or pharmaceutically acceptable salt thereof after storage for at least 12 months at room temperature.5. The pharmaceutical product of claim 1 , wherein the formulation is contained within a clear glass vial.6. The pharmaceutical product of claim 1 , wherein the amounts of T3 and total impurities are determined by a peak area percent method using high-performance liquid chromatography (HPLC).7. The pharmaceutical product of claim 1 , wherein the formulation comprises levothyroxine sodium at a concentration of about 100 mcg/mL.8. A pharmaceutical product comprising an aqueous formulation for parenteral administration claim 1 , the formulation comprising levothyroxine sodium at a ...

COMPOSITIONS AND METHODS FOR ENHANCING RECOVERY AFTER SURGERY OR AN ATHLETIC PERFORMANCE

The invention provides compositions and dosage forms, e.g., in the form of dietary supplements, such as pills, tablets, beverages, or gels, that enhance recovery after surgery or after an athletic performance. An exemplary composition or dosage form comprises about 5000 IU of vitamin A, about 15 mg of vitamin B1, about 34 mg of vitamin B2, about 25 mg of vitamin B3, about 50 mg of vitamin B5, about 20 mg of vitamin B6, about 90 μg of vitamin B12, about 300 mg of vitamin C, about 500 IU of vitamin D, about 60 IU of vitamin E, about 160 μg of vitamin K1, about 5 μg of vitamin K2, about 300 μg of biotin, about 400 μg of folate, about 30 μg of PABA, about 1 mg of boron, about 200 μg of chromium, about 500 μg of copper, about 150 mg of magnesium, about 5 μg of manganese, about 100 μg of molybdenum, about 135 μg of selenium, about 100 μg of vanadium, about 20 mg of zinc, about 150 μg of iodine, about 1.2 mg of pomegranate extract, about 250 mg of bromelain, and about 250 mg of quercetin. Methods for using the compositions and dosage forms for enhancing recovery after surgery or after an athletic performance are also provided herein. The invention also provides kits comprising a composition or dosage form described herein. 1. A composition comprising(a) vitamin B and/or vitamin E;(b) boron;(c) a protease and(d) a flavonoid.2. The composition of claim 1 , wherein the B vitamin is selected from the group consisting of vitamin B1 claim 1 , vitamin B2 claim 1 , vitamin B3 claim 1 , vitamin B5 claim 1 , vitamin B6 claim 1 , vitamin B12 claim 1 , and combinations thereof.3. The composition of claim 2 , wherein the Vitamin B1 comprises thiamine claim 2 , the Vitamin B2 comprises riboflavin claim 2 , the Vitamin B3 comprises niacin claim 2 , the Vitamin B5 comprises pantothenic acid and/or pantothenate claim 2 , the Vitamin B6 comprises pyridoxine and/or pyridoxal claim 2 , and/or the Vitamin B12 comprises cobalamin.4. The composition of claim 1 , wherein the composition further ...

Multi-nutrient supplement and uses thereof

Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

Pet Hydration System

A pet hydration system comprising of specific ranges of vitamins and minerals conducive to a pet's health, with such nutrients placed into a liquid beverage and ultimately dispensed via a compartmentalized beverage dispenser. The compartmentalized beverage dispenser is formed such that separate liquids are measured out and dispensed to the pet in a manner that the pet receives the optimal amount of nutrition. 1. A pet hydration system , comprising:mixing minerals into a liquid beverage;mixing vitamins into the liquid beverage;mixing calcium into the liquid beverage such that no less than 0.70 g and no more than 0.80 g of the calcium is included into each dispensed dose of the liquid beverage that is dispensed to a dog;mixing phosphorus into the liquid beverage such that no less than 0.70 g and no more than 0.80 g of the phosphorus is included into each dispensed dose of the liquid beverage that is dispensed to a dog;mixing magnesium into the liquid beverage such that no less than 140 mg and no more than 160 mg of the magnesium is included into each dispensed dose of the liquid beverage that is dispensed to a dog;mixing sodium into the liquid beverage such that no less than 90 mg and no more than 110 mg of the sodium is included into each dispensed dose of the liquid beverage that is dispensed to a dog;mixing potassium into the liquid beverage such that no less than 0.5 g and no more than 1.5 g of the potassium is included into each dispensed dose of the liquid beverage that is dispensed to a dog;mixing chlorine into the liquid beverage such that no less than 140 mg and no more than 160 mg of the chlorine is included into each dispensed dose of the liquid beverage that is dispensed to a dog;mixing iron into the liquid beverage such that no less than 7 mg and no more than 8 mg of the iron is included into each dispensed dose of the liquid beverage that is dispensed to a dog;mixing copper into the liquid beverage such that no less than 1 mg and no more than 2 mg of the ...

SYNERGISTIC ANTIBACTERIAL ACTIVITY OF MEDIUM POLARITY OILS IN COMBINATION WITH ANTIBACTERIAL AGENTS ON BACTERIAL BIOFILMS

The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms. 1114-. (canceled)115. A method of treating a wound , mucous membrane lesion , or skin lesion infected or contaminated with a bacterial biofilm , the method comprising topically administering to the wound , mucous membrane lesion , or skin lesion a composition comprising a combination of at least one medium polarity oil having an octanol-water partition coefficient (log P) of 0.5 to 2.0 and at least one silver compound , wherein the medium polarity oil is benzyl alcohol or propyl gallate.116. The method of claim 115 , wherein the silver compound is silver nitrate claim 115 , silver sulfadiazine claim 115 , or silver chloride.117. The method of claim 115 , wherein the silver compound is silver nitrate.118. The method of claim 115 , wherein the silver compound is at a concentration of 0.1% w/w to 5% w/w claim 115 , and the medium polarity oil is at a concentration of 1% w/w to 10% w/w.119. The method of claim 115 , wherein the silver compound is at a concentration of 0.1% w/w to 1.5% claim 115 , and the medium polarity oil is at a concentration of 4.5% w/w to 5.5% w/w.120. The method of claim 119 , wherein the silver compound is silver nitrate.121. The method of claim 115 , wherein the composition further comprises a pharmaceutical carrier.122. The method of claim 121 , wherein the pharmaceutical carrier is a lotion claim 121 , solution claim 121 , suspension claim 121 , liquid claim 121 , emulsion claim 121 , cream claim 121 , gel claim 121 , ringing ...

BIOFILM DISRUPTING COMPOSITION FOR USE ON CHRONIC WOUNDS

A biofilm disrupting composition for use on chronic wounds comprising (i) at least one biologically acceptable thiol based antioxidant(ii) at least one biofilm disruptor and (iii) at least one biocide. Also disclosed is a process of preparing the composition. Also disclosed is the use of the composition for the manufacture of a medicament for the treatment of a chronic wound, and a method of treating a chronic wound in a patient comprising administering the biofilm disrupting composition. 126-. (canceled)27. A biofilm disrupting composition when used for treatment of chronic wounds comprising:(i) at least one biologically acceptable thiol based antioxidant;(ii) at least one biofilm disruptor; and(iii) at least one biocide.28. The composition according to wherein the biologically acceptable thiol based antioxidant is selected from the group consisting of mercaptoethanol claim 27 , N-acetyl cysteine claim 27 , glutathione claim 27 , thiamphenicol glycinate acetylcysteinate claim 27 , sodium mercaptoethane sulfonate claim 27 , lipoic acid and erdosteine.29. The composition according to wherein the biologically acceptable thiol based antioxidant is glutathione.30. The composition according to wherein the biofilm disruptor is at least one enzyme selected from the group consisting of amylase claim 27 , cellulase claim 27 , DNase and protease claim 27 , or mixtures thereof.31. The composition according to wherein the enzyme is DNase.32. The composition according to wherein the biocide is selected from the group consisting of an antibiotic and an antiseptic.33. The composition according to wherein the biocide is a topical antibiotic selected from the group consisting of sulfacetamide sodium claim 32 , erythromycin claim 32 , silver sulfadiazine claim 32 , mupirocin claim 32 , bacitracin claim 32 , neomycin claim 32 , polymyxin claim 32 , bacitracin claim 32 , neomycin claim 32 , polymyxin B and pramoxine.34. The composition according to wherein the antiseptic is selected ...

TOPICAL ANTISEPTIC SYSTEM

Novel antimicrobial compositions and kits thereof containing these antimicrobial compositions, methods of manufacture and methods of use thereof are disclosed. The novel aqueous transdermal or topical delivery systems are useful, inter alia, for treatment of various microbial infections, including for use on tissue infections, particularly skin antisepsis and/or nasal mucosal tissue antisepsis to a mammalian host in need thereof. 137-. (canceled)38. A method of disinfecting tissue comprising: 'an iodophor comprising a carrier selected from the group consisting of a polyvinylpyrrolidone, a copolymer of N-vinyl lactam, a polyether glycol, a polyvinyl alcohol, a polyacrylamide, a polysaccharide, and combinations thereof;', 'applying directly to tissue an antiseptic composition at use concentration, wherein the use concentration of the antiseptic composition comprises a second antimicrobial agent;', 'a nonionic or anionic surfactant;', 'a thickening agent comprising a nonionic cellulose derivative or nonionic copolymer, or combination thereof; and', 'water;', said antiseptic composition is substantially free of any hydroxycarboxylic acid buffer; and', 'said antiseptic composition is substantially free of any fragrance; and, 'wherein], 'wherein the iodophor is present in an amount sufficient to provide an available iodine concentration of at least 0.25 wt-%;'}allowing the antiseptic composition to remain on the tissue; wherein the composition has a pH of 1.5 to 6.5.3941-. (canceled)42. A method according to wherein the nonionic copolymer comprises hydrophilic and hydrophobic regions.43. A method according to claim 42 , wherein the nonionic copolymer comprises a poloxamer.44. (canceled)45. A method of disinfecting skin of a subject comprising: prior to an invasive procedure claim 42 , a first antimicrobial agent selected from the group consisting of 12, an iodophor, and a combination thereof, wherein the antimicrobial agent is present in an amount sufficient to provide an ...

Dietetic multi-component system

An improved multi-component system containing a main component and at least one additional component that is physically separated from the main component, and a use of the system as a food supplement and a pharmaceutical product.

COMPOSITIONS OF AND METHODS FOR DAIRY ANIMAL TEAT DIP

An improved aqueous teat dip comprising iodine and chlorhexidine in an aqueous solution. 1. A teat dip comprising:iodine and chlorhexidine salt,wherein the iodine comprises a mixture of sodium iodide and an iodophore;wherein the chlorhexidine salt is selected from one of chlorhexidine hydrochloride, chlorhexidine lactate, chlorhexidine phosphate, and chlorhexidine gluconate;wherein the iodine comprises about 0.1 to 5 weight percent of the teat dip;wherein the chlorhexidine salt comprises about 0.2 to 4 weight percent of the teat dip;wherein sodium iodide comprises between 10% and 100% of the iodine; andwherein the iodophore comprises the remaining iodine in the teat dip.2. The teat dip of further comprising a surfactant.3. The teat dip of claim 1 , wherein the iodine comprises about 0.5 weight percent of the teat dip.4. The teat dip of claim 1 , wherein the iodophore is iodine complexed with a surfactant.5. The teat dip of claim 1 , wherein the chlorhexidine salt is chlorhexidine gluconate.6. The teat dip of claim 1 , wherein chlorhexidine salt comprises about 0.5% of the teat dip.7. The teat dip of claim 2 , wherein the surfactant further comprises an ethoxylate.8. The teat dip of claim 1 , wherein iodide comprises 0.20% by weight of the teat dip.92. The teat dip of claim of claim 1 , wherein the surfactant comprises from about 3 from about 15 weight percent.10. The teat dip of claim 1 , further comprising at least one buffering agent.11. The teat dip of claim 1 , further comprising at least on emollient.12. The teat dip of further comprising a humectant.13. The teat dip of wherein the humectant is selected from the group consisting of: glycerine; sorbitol; and propylene glycol.14. The teat dip of wherein the humectant comprises from about 0.5 from about 15 weight percent.15. The teat dip of further comprising at least one thickener.16. The teat dip of further comprising at least one colorant.17. The teat dip of having a pH of between 4.5 and 7.5.18. The teat dip ...

TRACE ELEMENT SOLUTION

A trace element solution comprises at least the following metals zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide; manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate; copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate, and/or copper carbonate; selenium derived directly and/or indirectly from NaSeOand/or NaSeO. The metals are present in a solution of water, chlorocresol and/or benzyl alcohol, at a concentration of metals of at least 95 mg/ml. The pH of the trace element solution adjusted by means of 30% NaOH in an injectable trace element solution that is visually stable. 1. A trace element solution , which comprises at least the following metals:(a) zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide;(b) manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate;(c) copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate, and/or copper carbonate; and{'sub': 2', '4', '2', '3, '(d) selenium derived directly and/or indirectly from NaSeOand/or NaSeO,'}wherein the metals are present in a solution of water, chlorocresol and/or benzyl alcohol, at a concentration of metals of at least 95 mg/ml; andwherein the pH of the trace element solution adjusted by means of 30% NaOH in an injectable trace element solution that is visually stable.2. The trace element solution of claim 1 , wherein zinc is present in at least 65 mg/ml zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide.3. The trace element solution of claim 1 , wherein manganese is present in at least 10 mg/ml manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate.4. The trace element solution of claim 1 , wherein copper is present in at least 15 mg/ml copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate claim 1 , and/or copper carbonate.5. The trace element solution of claim 1 , wherein selemium is present in at least ...

INACTIVATION OF PAPILLOMAVIRUS

A method of treating early papillomavirus infection of an orifice of a human or animal body including any canal associated with an orifice, comprising applying a viral inactivation agent to the orifice and/or canal in an amount effective to inactivate a portion of the virus infecting the orifice or canal. Apparatus is also disclosed. 126-. (canceled)27. A method of treating early papillomavirus infection of an orifice of a human or animal body , comprising any canal associated with an orifice , comprising applying a viral inactivation agent to the orifice or canal in an amount effective to inactivate a portion of the virus infecting the orifice or canal.28. The method of claim 27 , where the papillomavirus is human papillomavirus and the body is a human body.29. The method of claim 28 , where the orifice and associated canal is a uterine cervix.30. The method of claim 29 , where the viral inactivation agent is applied so that the agent infuses cell structure of the orifice or canal through to the basal cell layer where the reservoir of the human papillomavirus resides claim 29 , and further infuses into the multitudinous gland structures and cavities in the walls of the endocervical canal.31. The method of claim 30 , where the viral inactivation agent is applied under pressure.32. The method of claim 28 , where the viral inactivation agent is an iodine-containing substance.33. The method of claim 30 , where the viral inactivation agent is an iodine-containing substance.34. The method of claim 31 , where the viral inactivation agent is applied under pressure.35. The method of claim 27 , where the orifice and associated canal is an anus.36. The method of claim 35 , where the viral inactivation agent is an iodine-containing substance.37. The method of claim 27 , where there is no hypersensitivity or allergic or other serious adverse reaction to the application of the viral inactivation agent to the orifice or canal.38. A method of preventing the development of a ...

Method and Apparatus for Using Iodinated Polymer as an Antimicrobial Agent to Manage the Suppression and Disinfection of Pathogens

Disclosed is a method and apparatus for using iodinated polymer as an antimicrobial agent to manage the suppression and disinfection of pathogens.

SMALL MOLECULE DUAL-INHIBITORS OF TRPV4 AND TRPA1 FOR SANITIZING AND ANESTHETIZING

Provided are methods of sanitizing a subject, and methods of anesthetizing a subject. Further provided are methods of treating and/or preventing dermatological disorders, reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof. The methods may include administering to the subject an effective amount of a TRPA1 and/or TRPV4 inhibitor. Further provided are compositions including a TRPA1 and/or TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application. 1. A composition comprising an inhibitor and iodine , wherein the inhibitor inhibits TRPV4 , TRPA1 , or a combination thereof.2. A composition comprising an inhibitor and an anesthetic , wherein the inhibitor inhibits TRPV4 , TRPA1 , or a combination thereof.3. The composition of or wherein the inhibitor does not inhibit TRPV1 , TRPV2 , or TRPV3.6. A method of sanitizing a subject , the method comprising contacting the subject with the composition of any one of and -.7. The method of claim 6 , wherein the subject is contacted with the composition for a period of time sufficient to cause a reduction in the population of microorganisms on the subject.8. The method of or claim 6 , wherein the composition is administered to a surface of the subject claim 6 , wherein the surface is selected from the group consisting of a skin area claim 6 , a wound claim 6 , and an ulcer.9. The method of any one of - claim 6 , wherein the composition disinfects the subject.10. The method of any one of - claim 6 , wherein the composition sterilizes the subject.11. The method of any one of - claim 6 , wherein the composition has antibacterial activity.12. A method of anesthetizing a subject claim 6 , the method comprising administering to the subject the composition of any one of -.13. A method of anesthetizing a subject claim 6 , the method comprising co-administering an anesthetic and an inhibitor to the subject claim 6 , wherein the inhibitor ...

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

PREVENTION OF INFECTION BY HIGHLY PATHOGENIC VIRUSES USING TOPICAL APPLICATION OF POVIDONE-IODINE ON MUCOUS MEMBRANES

This invention is directed to methods for prevention of infections by highly pathogenic viruses by applying to the nasal mucous membranes topical preparations comprising the broad-spectrum antimicrobial agent povidone-iodine. 1. A method of reducing the risk , incidence or severity of systemic illness in a human subject caused by SARS-CoV-2 , the method comprising application to the nasal passages of the human subject an effective amount of a pharmaceutical preparation comprising povidone-iodine (PVP-I) at a concentration of greater than 0.10% w/v and less than about 1.25% w/v and where the preparation is applied prior to , during and/or immediately after exposure or possible exposure of the subject to SARS-CoV-2 or to SARS-CoV-2 infected person.2. The method as claimed in wherein the PVP-I preparation is applied up to 12 times daily into the nasal passages of a human subject claim 1 , commencing prior to claim 1 , during or after exposure to the Filovirus and thereafter for a period approximately equivalent to the expected incubation period of the virus.3. A method as claimed in wherein the preparation is applied at a frequency of between 1 and 12 times daily commencing before claim 1 , after or around the time of exposure to the SARS-CoV-2 and/or thereafter.4. The method as claimed in wherein the human subject is a healthcare worker who is claim 1 , or is likely to be claim 1 , exposed to the SARS-CoV-2 or SARS-CoV-2 infected patients.5. The method as claimed in claim 4 , wherein the PVP-I preparation is applied by the healthcare worker prior to exposure.6. The method as claimed in claim 1 , wherein the PVP-I concentration in the pharmaceutical preparation applied to the nasal passages is about 0.1% to about 1.0% w/v.7. The method as claimed in claim 7 , wherein the PVP-I concentration in the pharmaceutical preparation applied to the nasal passages is about 0.2% to about 0.5% w/v.8. The method as claimed in wherein the pharmaceutical preparation is an aqueous ...

Nutritional composition

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.

NOVEL COMPOSITION METHOD OF USING THE SAME FOR THE TREATMENT OF LYME DISEASE

A composition for treating Lyme disease caused by Species, comprising a vitamin, a small fatty acid signaling molecule, an essential amino acid, a flavonoid, a plant extract and a mineral. 1. A composition , comprising:a mixture having a specific concentration of at least one of a Vitamin, a Small chain fatty acid signaling molecule, an Essential Amino Acid, a Lauric acid derivative, a Flavonoid, a Phenol, a Plant Extract, and a Mineral for treating a Lyme disease.2Aronia. The composition of claim 1 , wherein the vitamin is at least one of a Vitamin C claim 1 , Vitamin B complex and Vitamin D3 claim 1 , the small fatty acid signaling molecule is Cis-2-decenoic acid claim 1 , the essential amino acid is at least one of a L-Lysin claim 1 , Aminocaproic acid and Tranexamic acid claim 1 , the flavonoid is at least one of a Luteolin claim 1 , Apigenin claim 1 , Baicalein claim 1 , Fisetin claim 1 , Kaempherol claim 1 , Myricetin and Quercetin 3D claim 1 , the plant extract is at least one of a Oleuropein claim 1 , Teasel Root Extract claim 1 , Oregano Oil claim 1 , Kelp claim 1 , Monolaurin claim 1 , Nordihydroguaiaretic acid claim 1 , Fucoinad claim 1 , Olein claim 1 , Rosmarinic acid claim 1 , Morin claim 1 , claim 1 , Rottlerin claim 1 , Malvidin claim 1 , Grape seed extract (OPC) claim 1 , Piceatannol the phenol is at least one of a Ellagic acid and E-Viniferin and the mineral is an Kelp (Iodine).3. The composition of claim 1 , wherein the mixture is at least one of a Mix A claim 1 , Mix A1 claim 1 , Mix B claim 1 , Mix C claim 1 , Mix D claim 1 , Mix E claim 1 , Mix F claim 1 , Mix G claim 1 , Mix H claim 1 , Mix I claim 1 , Mix J claim 1 , Mix K claim 1 , Mix L claim 1 , Mix M claim 1 , Mix N claim 1 , Mix O claim 1 , Mix AO and Mix P.4. The composition of claim 1 , wherein the mixture is a Mix A claim 1 , wherein the Mix A consists of a Vitamin D3 claim 1 , Cis-2-Decenoic acid claim 1 , Kelp (Iodine) claim 1 , Monolaurin claim 1 , Luteolin and Rosmarinic acid.5. ...

ORAL MOLECULAR IODINE COMPOSITION AND METHOD

Oral pharmaceutical compositions comprising iodide, iodate and. arachidonic acid in the presence of other pharmaceutical excipients and methods for preparing and using these compositions. 1. An oral pharmaceutical composition comprising:a. iodide and iodate in a re-oxidation ratio of between about 1.1 to about 2.0;b. at least one pharmaceutically acceptable excipient; andc. at least one pH control agent;wherein the effective pH of the composition is between about 7.0 and 12.0; 'wherein there is excess iodate remaining after the initial oxidation of substantially all of the iodide in the table; and', 'wherein the concentration of iodide and iodate is substantially identical throughout the composition;'}wherein the iodide and iodate in the composition delivers molecular iodine to the stomach of a subject when administered to the subject.2. An oral pharmaceutical composition comprising:a. iodide and iodate in a re-oxidation ratio of between about 1.1 to about 2.0, wherein the iodide and iodate in the composition delivers molecular iodine to the stomach of a subject when administered to the subject;b. arachidonic acid, wherein the molar ratio of arachidonic acid to molecular iodine formed in the stomach is between about 1.1 to about 100;c. at least one pharmaceutically acceptable excipient; andd. at least one pH control agent;wherein the molecular iodine formed in the stomach of the subject reacts with the arachidonic acid to form an iodinated lipid;wherein the concentration of iodide and iodate is substantially identical throughout the composition; andwherein the effective pH of the composition is between about 7.0 and 12.0.3. The method of claim 2 , wherein molar ratio of arachidonic acid to molecular iodine is between about 5 to about 90.4. The method of claim 2 , wherein molar ratio of arachidonic acid to molecular iodine is between about 10 to about 80.5. The method of claim 2 , wherein molar ratio of arachidonic acid to molecular iodine is about 50.6. The method ...

Method for the Prevention and Treatment of Cancer, Tuberculosis and Related Diseases

A method for preventing and treating one or more disease states including the steps of altering the diet of an individual and then administering a drug to the individual. Plasma vitamin C level is reduced from a first level to a second level that is lower than the first level, such that a pharmacological response of the body of the individual to a drug at the first level is different from the pharmacological response of the body of said individual to the drug at the second level. 1. A method for preventing and treating one or more disease states , the method comprising the steps of:a) altering a diet of an individual having a plasma vitamin C level in order to reduce the plasma vitamin C level from a first level to a second level that is lower than the first level, wherein a pharmacological response of the body of said individual to a drug at the first level is different from the pharmacological response of the body of said individual to the drug at the second level; andb) administering said drug to said individual.2. The method according to further comprising the step of measuring the plasma vitamin C level of said individual prior to administering the drug.3. The method according to claim 1 , wherein the plasma vitamin C level is maintained at the second level for at least one month.4. The method according to further comprising the step of administering an anti-vitamin C substance to the individual prior to administering the drug to reduce the plasma vitamin C level from the second level to a third level that is lower than the first or second levels.5. The method according to claim 4 , wherein administering the anti-vitamin C substance causes a fulminating scurvy condition to occur in the individual.6. The method according to claim 4 , wherein the anti-vitamin C substance is selected from the group consisting of a metal substance claim 4 , a metalloid substance claim 4 , an organic agent claim 4 , an oxidizing agent claim 4 , an infectious agent claim 4 , and ...

COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION

A method for improving a nutritional status in a prenatal, pregnant or breastfeeding patient. The method includes providing a pharmaceutical composition in a single oral dosage form for administration to a prenatal, pregnant or breastfeeding patient. The pharmaceutical composition consists of vitamin D, iodine, vitamin B1, vitamin B6, vitamin B12, vitamin B2, vitamin B9, vitamin B3, vitamin E, vitamin A, vitamin C, iron, zinc, copper, magnesium, omega-3 fatty acids and one or more pharmaceutically acceptable carriers. The method further includes providing a daily dosage regimen for administering the single oral dosage form to the patient to improve a nutritional status in the patient. 1. A method for improving a nutritional status in a prenatal , pregnant or breastfeeding patient , the method comprising:providing a pharmaceutical composition in a single oral dosage form for administration to a prenatal, pregnant or breastfeeding patient, the pharmaceutical composition consisting of: vitamin D in an amount of about 500 I.U. to about 1500 I.U., iodine in an amount of about 75 μg to about 225 μg, vitamin B1 in an amount of about 0.8 mg to about 2.4 mg, vitamin B6 in an amount of about 1.2 mg to about 3.8 mg, vitamin B12, vitamin B2 in an amount of about 0.9 mg to about 2.7 mg, vitamin B9 in an amount of about 0.5 mg to about 1.5 mg, vitamin B3 in an amount of about 7.5 mg to about 22.5 mg, vitamin E in an amount of about 10 I.U. to about 30 I.U., vitamin A in an amount of about 550 I.U. to about 1650 I.U., vitamin C, iron, zinc in an amount of about 12.5 mg to about 37.5 mg, copper in an amount of about 1.0 mg to about 3.0 mg, magnesium in an amount of about 10 mg to about 30 mg, omega-3 fatty acids in an amount of about 100 mg to about 300 mg and one or more pharmaceutically acceptable carriers; andproviding a daily dosage regimen for administering the single oral dosage form to the patient to improve a nutritional status in the patient.2. The method of claim 1 , ...

EDIBLE BROWN ALGAE EXTRACT WITH A LOW IODINE CONTENT

The invention relates to a brown algae extract containing less than 50 ppm of iodine and between 5 and 15%, and preferably between 8 and 10%, of polyphenols, said percentage of polyphenols being expressed as a chlorogenic acid equivalent in relation to the dry weight of the extract, the invention also relating to an oral absorption composition comprising such an extract, and to a method for preparing the extract according to the invention. 1. Algae extract , comprising less than 50 ppm of iodine and between 5 and 15% of polyphenols , said percentage of polyphenols being expressed in chlorogenic acid equivalent compared with the dry matter of the extract.2. Algae extract according to claim 1 , comprising between 8 and 10% of polyphenols claim 1 , said percentage of polyphenols being expressed in chlorogenic acid equivalent compared with the dry matter of the extract.3. Algae extract according to claim 1 , wherein said algae are brown.4. Algae extract according to claim 1 , wherein said algae are food algaes.5. Algae extract according to claim 1 , comprising between 5 and 9% of alginates claim 1 , said percentage of alginates being expressed in glucuronic acid equivalent compared with the dry matter of the extract.6. Algae extract according to claim 1 , comprising the majority of minerals content claim 1 , except iodine claim 1 , present in said algae before their processing by extraction.7AscophyllumFucusHimanthaliaUndariaLaminaria. Algae extract according to claim 1 , wherein said algae belongs to at least one of the following species: sp. claim 1 , sp. claim 1 , sp. claim 1 , sp. claim 1 , and sp.8. Composition for oral intake comprising an algae extract such as defined according to .9. Composition for oral intake according to claim 8 , wherein the composition is free from any carrier.10. Composition for oral intake according to claim 8 , comprising an acceptable carrier for oral intake claim 8 , present in said extract in a content of 0.5% to 5 wt % compared with ...

Ocular cross-linking system and method for sealing corneal wounds

Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.

COMPOSITIONS

The disclosure describes a composition including about 4 weight percent to about 12 weight percent of povidone-iodine complex, about 0.1 weight percent to about 2 weight percent of a tertiary amide, tertiary amide salt, and/or tertiary amide hydrate, about 0.5 weight percent to about 2 weight percent of an emollient with low iodine reactivity, at least one surfactant; and water; wherein the composition has a pH ranging from about 2.0 to about 3.5. 1. A composition comprising:about 4 weight percent to about 12 weight percent of povidone-iodine complex,about 0.1 weight percent to about 2 weight percent of a tertiary amide, tertiary amide salt, and/or tertiary amide hydrate,about 0.5 weight percent to about 2 weight percent of low iodine reactive emollient,at least one surfactant; andwater;wherein the composition has a pH ranging from about 2.0 to about 3.5.2. The composition of claim 1 , wherein the weight percent of the povidone-iodine complex is between about 5 and about 10.3. The composition of claim 1 , wherein the weight percent of the povidone-iodine complex is between about 6 and about 9.4. The composition of claim 1 , wherein the low iodine reactive emollient has an iodine number of less than about 80.5. The composition of claim 1 , wherein the low iodine reactive emollient has an iodine number of less than about 25.6. The composition of claim 1 , wherein the low iodine reactive emollient has an iodine number of less than about 10.7. The composition of claim 1 , wherein the low iodine reactive emollient has an iodine number of less than about 5.8. The composition of claim 1 , wherein the low iodine reactive emollient is selected from the groups consisting of jojoba oil claim 1 , hydrogenated jojoba esters claim 1 , hydrogenated polybutenes claim 1 , isododecane claim 1 , glyceryl tribehenate claim 1 , hydrogenated castor oil claim 1 , palm oil claim 1 , derivatives thereof and combinations thereof.9. The composition of claim 1 , wherein the low iodine reactive ...

METHOD FOR TREATING FIBRILLAR COLLAGENOUS CONDITIONS

A topical composition can be used to treat or inhibit onset of fibrillar collagenous growths, including but not limited to keloids. The composition includes elemental iodine carried in a non-migratory vehicle. Application of the composition can result in a significant reduction in the size of such a growth or, if applied to an area of skin susceptible to such a growth, inhibit the onset thereof. 1. (canceled)2. A method for treating a fibrillar collagenous growth , said method comprising (a) providing to a human in need thereof a treating composition that comprises elemental iodine carried in a non-migratory vehicle and (b) instructing said human to apply said composition to said growth.3. The method of wherein said treating composition is provided in a kit that further comprises instructions.4. The method of wherein said kit further comprises a tool adapted for applying said composition to said growth.5. The method of wherein said kit further comprises a container adapted to meter a predetermined amount of said composition onto said growth.6. The method of wherein said treating composition is an iodophor.7. The method of wherein said non-migratory vehicle is a water soluble modified starch.8. The method of wherein said nonmigratory vehicle is a modified starch.913-. (canceled)14. A method for inhibiting onset of a fibrillar collagenous growth claim 3 , said method comprising (a) providing to a human in need thereof a treating composition that comprises elemental iodine carried in a non-migratory vehicle and (b) instructing said human to apply said composition to an area of skin susceptible to said growth.15. The method of wherein said treating composition is provided in a kit that further comprises instructions.16. The method of wherein said kit further comprises a tool adapted for applying said composition to said growth.17. The method of wherein said kit further comprises a container adapted to meter a predetermined amount of said composition onto said growth.18. ...

ANTIFUNGAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND NAILS

Improvements in or relating to manually operated dispense heads for fluid containers 1. A composition for treating an ungual infection , the composition comprising:(a) an iodophor; and(b) dimethylsulfoxide (DMSO);wherein the composition is capable of penetrating the unguis to treat the infection.2. A composition for treating an ungual infection , the composition comprising:(a) elemental iodine; and(b) dimethylsulfoxide (DMSO);wherein the composition is capable of penetrating the unguis to treat the infection.3. The composition of claim 1 , wherein the iodophor is selected from the group consisting of povidone iodine (PVP-I) claim 1 , iodine tincture claim 1 , Lugol's solution claim 1 , potassium iodide claim 1 , and sodium iodide.4. The composition of claim 3 , where in the iodophor is PVP-I.5. The composition of claim 1 , wherein the composition is substantially anhydrous.6. The composition of claim 1 , wherein the composition is anhydrous.7. The composition of claim 3 , wherein PVP-I is present at about 0.01% to about 10% (w/w).8. The composition of claim 3 , wherein PVP-I is present in a range selected from the group consisting of about 0.05% to about 10% claim 3 , about 0.1% to about 5% claim 3 , about 0.2% to about 2.5% claim 3 , and about 0.5% to about 1% (w/w).9. The composition of claim 3 , wherein PVP-I is present in a range selected from the group consisting of about 0.1% claim 3 , about 0.2% claim 3 , about 0.3% claim 3 , about 0.4% claim 3 , about 0.5% claim 3 , about 1.0% claim 3 , about 1.25% claim 3 , about 1.5% claim 3 , about 2.0% claim 3 , about 2.5% claim 3 , and about 5% (w/w).10. The composition of claim 3 , wherein PVP-I is present at about 1% (w/w).11. The composition of claim 1 , further comprising at least one naturopathic substance.12. The composition of claim 1 , further comprising at least one substance selected from the group consisting of Punica Granatum Extract claim 1 , Camellia Sinensis Leaf Extract claim 1 , Ascorbic Acid claim 1 , ...

NUTRITIONAL SUPPLEMENT SYSTEM

A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12. 1. A nutritional supplement system for human subjects , a daily dose of the nutritional supplement system comprising phosphorus , magnesium , zinc , manganese , boron , copper , chromium , molybdenum , nickel , tin , vanadium , selenium , silicon , calcium , iodine , vitamin A , vitamin B1 , vitamin B2 , vitamin B3 , vitamin B5 , vitamin B6 , vitamin B12 , vitamin C , vitamin D , vitamin E , folic acid , biotin , lutein , lycopene , one or more omega-3 fatty acids , and one or more tocopherols , the daily dose of the nutritional supplement system consisting essentially of four nutritional supplement dosage units , wherein:a first nutritional supplement dosage unit comprises one or more nutrients being selected from phosphorus, magnesium, vitamin C, zinc, vitamin E, manganese, vitamin B3, boron, copper, vitamin A, beta carotene, vitamin B5, chromium, molybdenum, nickel, tin, vanadium, iron, selenium, vitamin K, N-acetyl cysteine, silicon, vitamin B6, vitamin B1, vitamin B2, vitamin B12, vitamin D, folate, folic acid, biotin, iodine and any combination thereof, the first dosage unit being in the form of at least one first dosage element formulated to release one or more nutrients in the stomach of a human subject;a second nutritional supplement dosage unit comprises one or more nutrients being selected from lutein, lycopene, vitamin D, vitamin E, omega-3 fatty acids, gamma tocopherol, beta tocopherol, delta tocopherol, and any combination thereof, the second dosage unit being in the form of at least one second dosage element formulated to release one or more nutrients in the upper intestinal tract of the subject;a third ...

Automated method and system for introducing Liquid iodine into drinking water

A system for delivering molecular iodine or other substance into a pet's drinking water on a daily basis without exceeding the safe amount allowed for the pet. The system delivers a particular amount of molecular iodine into the pet water supply to achieve maximum benefit of Ito reduce or eliminate bad pet breath and minimize total iodine in the pet diet so that 20-40 μg/mL/Kg/day iodine is consumed for optimum thyroid health. The preferred method is to use a solution created by dissolving iodine crystals in absolute ethanol. The iodine will only be in solution as Ifor a short time as it undergoes out gassing and hydrolysis at neutral pH. The present invention removes the iodine from the drinking water after the pet drinks. Therefore, during the day, pets will get no additional iodine—only fresh water. Each enrolled pet is electronically recognized by the system. 1. An apparatus for injecting molecular iodine into pet drinking water comprising:a pet-access drinking container;a dual filter cartridge containing both an activated charcoal filter and a hair filter;a continuously-running circulation pump, wherein the circulation pump is adapted to pass water from the pet-access drinking container through the filter cartridge to remove excess molecular iodine;a molecular iodine dispenser containing a solution of molecular iodine in absolute alcohol constructed to dispense the molecular iodine solution into the pet-access drinking container, the solution of molecular iodine being a 1% solution;a pet identification module adapted to read a passive RFID tag worn by a pet to produce a pet identification;a processor programmed use pet identification to recognize a pet and then dispense 20-40 ug/mL/Kg/day of iodine of said molecular iodine solution from said molecular iodine dispenser into said drinking container based on a stored profile for that pet;2. The apparatus of wherein the pet-access drinking container is flushed of molecular iodine after a pet drinks.3. The apparatus ...

TRACE ELEMENTS

A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium. 120-. (canceled)21. A trace element aqueous injectable solution for veterinary use , comprising zinc , copper , and at least one other trace element , wherein the concentration of zinc ranges from 60 mg/ml up to a concentration that , in combination with said copper and said at least one other trace element , preserves the suitability for injection of the trace element aqueous injectable solution.22. A trace element aqueous injectable solution for veterinary use of wherein said trace element aqueous solution is tissue friendly.23. A trace element aqueous injectable solution for veterinary use claim 21 , comprising zinc claim 21 , manganese claim 21 , and at least one other trace element claim 21 , wherein the concentration of zinc ranges from 60 mg/ml up to a concentration that claim 21 , in combination with said manganese and said at least one other trace element claim 21 , preserves the suitability for injection of the trace element aqueous injectable solution.24. A trace element aqueous injectable solution for veterinary use of wherein said trace element aqueous solution is tissue friendly.25. A method of improving trace element amounts in an animal comprising administering a trace element aqueous injectable solution for veterinary use claim 23 , comprising zinc claim 23 , copper claim 23 , and at least one other trace element claim 23 , wherein the concentration of zinc ranges from 60 mg/ml up to a concentration that claim 23 , in combination with said copper and said at least one other trace element claim 23 , preserves the suitability for injection of the trace ...